Diagnoses of HIV Infection in the United States and Dependent Areas, 2021: Tables

All Tables
Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 30,444 29,602 28,809 24,174 28,304
Female 7,288 7,055 6,900 5,421 6,554
Transgender woman/girlb 651 661 692 676 811
Transgender man/boyb 32 48 45 41 56
Additional gender identityc 18 19 32 23 44
Age at diagnosis (yr)
< 13 105 0.2 86 0.2 57 0.1 60 0.1 53 0.1
13–14 25 0.3 20 0.2 21 0.3 12 0.1 15 0.2
15–19 1,791 8.5 1,722 8.2 1,652 7.8 1,264 5.9 1,452 6.7
20–24 6,481 29.4 6,123 28.1 5,987 27.7 4,849 22.6 5,460 25.4
25–29 7,720 33.0 7,682 32.6 7,382 31.4 6,080 26.7 6,713 30.0
30–34 5,680 25.9 5,664 25.6 5,645 25.1 5,199 22.7 6,368 27.6
35–39 4,254 20.1 4,186 19.4 4,102 18.9 3,400 15.3 4,403 19.7
40–44 2,981 15.2 2,964 15.1 2,946 14.8 2,474 12.0 3,140 14.9
45–49 2,926 14.0 2,759 13.3 2,571 12.6 2,044 10.1 2,326 11.8
50–54 2,637 12.4 2,435 11.7 2,303 11.3 1,828 8.8 2,116 10.1
55–59 1,869 8.5 1,824 8.3 1,837 8.4 1,558 7.1 1,786 8.3
60–64 1,082 5.4 1,042 5.1 1,106 5.4 879 4.2 1,095 5.2
≥ 65 882 1.7 878 1.7 869 1.6 688 1.3 842 1.5
Race/ethnicity
American Indian/Alaska Native 193 8.0 170 7.1 194 8.0 190 7.8 223 9.1
Asian 919 5.0 850 4.5 728 3.8 612 3.1 739 3.8
Black/African American 16,163 39.8 15,642 38.2 15,327 37.2 12,678 30.4 14,555 34.8
Hispanic/Latinod 10,010 17.1 9,931 16.7 9,858 16.3 8,046 13.0 10,070 16.1
Native Hawaiian/other Pacific Islander 47 8.1 57 9.6 59 9.8 64 10.3 76 12.1
White 9,558 4.8 9,338 4.7 8,992 4.6 7,744 3.9 9,063 4.6
Multiracial 1,543 22.0 1,397 19.4 1,320 17.9 1,001 13.1 1,043 13.4
Transmission categorye
Male sex at birth (≥ 13 yrs at diagnosis)f
Male-to-male sexual contactg 25,345 24,464 23,870 20,460 23,855
Injection drug useh 1,291 1,376 1,362 1,170 1,415
Male-to-male sexual contactg
and injection drug useh
1,517 1,531 1,581 1,185 1,373
Heterosexual contacti 2,882 2,839 2,643 2,006 2,460
Perinatalj 14 16 22 9 11
Otherk 18 17 20 16 18
Subtotal 31,067 23.3 30,242 22.6 29,498 21.9 24,846 18.1 29,132 21.1
Female sex at birth (≥ 13 yrs at diagnosis)f
Injection drug useh 1,109 1,117 1,182 895 1,075
Heterosexual contacti 6,106 5,892 5,695 4,494 5,456
Perinatalj 40 40 38 34 49
Otherk 6 7 7 6 5
Subtotal 7,261 5.2 7,057 5.0 6,923 4.9 5,429 3.8 6,584 4.6
Child (< 13 yrs at diagnosis)
Perinatal 89 69 47 51 39
Otherk 16 17 10 9 14
Subtotal 105 0.2 86 0.2 57 0.1 60 0.1 53 0.1
Region of residencel
Northeast 5,998 10.7 5,560 9.9 5,323 9.5 4,252 7.4 4,993 8.7
Midwest 5,119 7.5 4,953 7.3 4,774 7.0 4,115 6.0 4,824 7.0
South 19,707 15.9 19,273 15.5 18,982 15.1 15,566 12.3 18,728 14.7
West 7,609 9.8 7,599 9.8 7,399 9.4 6,402 8.1 7,224 9.2
Total 38,433 11.8 37,385 11.4 36,478 11.1 30,335 9.2 35,769 10.8

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data include transgender and additional gender identity persons.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 30,811 29,980 29,148 24,435 28,641
Female 7,382 7,136 6,983 5,467 6,636
Transgender woman/girlb 653 665 694 679 812
Transgender man/boyb 32 48 45 41 56
Additional gender identityc 18 19 32 23 44
Age at diagnosis (yr)
< 13 105 0.2 86 0.2 57 0.1 60 0.1 53 0.1
13–14 25 0.3 20 0.2 21 0.2 12 0.1 15 0.2
15–19 1,804 8.4 1,740 8.2 1,658 7.8 1,272 5.8 1,460 6.7
20–24 6,547 29.3 6,188 28.0 6,045 27.6 4,893 22.5 5,512 25.3
25–29 7,782 33.0 7,759 32.6 7,442 31.3 6,124 26.6 6,793 30.0
30–34 5,741 25.9 5,723 25.6 5,703 25.2 5,237 22.7 6,411 27.5
35–39 4,306 20.1 4,222 19.4 4,142 18.9 3,438 15.3 4,448 19.8
40–44 3,017 15.2 3,005 15.1 2,984 14.8 2,502 12.0 3,186 14.9
45–49 2,968 14.0 2,805 13.4 2,609 12.7 2,067 10.1 2,359 11.8
50–54 2,687 12.5 2,484 11.8 2,334 11.3 1,859 8.8 2,160 10.2
55–59 1,906 8.6 1,853 8.4 1,875 8.5 1,585 7.1 1,807 8.3
60–64 1,105 5.5 1,062 5.2 1,133 5.4 896 4.2 1,116 5.2
≥ 65 903 1.8 901 1.7 899 1.6 700 1.3 869 1.5
Race/ethnicity
American Indian/Alaska Native 193 170 194 190 223
Asian 922 854 735 612 740
Black/African American 16,168 15,654 15,335 12,685 14,561
Hispanic/Latinod 10,456 10,369 10,257 8,347 10,478
Native Hawaiian/other Pacific Islander 50 59 63 65 76
White 9,562 9,344 8,998 7,745 9,068
Multiracial 1,545 1,398 1,320 1,001 1,043
Transmission categorye
Male sex at birth (≥ 13 yrs at diagnosis)f
Male-to-male sexual contactg 25,587 24,742 24,110 20,660 24,107
Injection drug useh 1,325 1,401 1,385 1,189 1,436
Male-to-male sexual contactg
and injection drug useh
1,529 1,542 1,594 1,190 1,375
Heterosexual contacti 2,962 2,906 2,709 2,046 2,523
Perinatalj 14 16 22 9 11
Otherk 18 17 20 16 18
Subtotal 31,436 23.3 30,624 22.6 29,839 21.9 25,110 18.1 29,470 21.1
   Female sex at birth (≥ 13 yrs at diagnosis)f
Injection drug useh 1,118 1,120 1,188 898 1,077
Heterosexual contacti 6,190 5,970 5,773 4,536 5,536
Perinatalj 40 40 38 34 49
Otherk 6 7 7 6 5
Subtotal 7,355 5.2 7,138 5.0 7,006 4.9 5,475 3.8 6,666 4.6
   Child (< 13 yrs at diagnosis)
Perinatal 89 69 47 51 39
Otherk 16 17 10 9 14
Subtotal 105 0.2 86 0.2 57 0.1 60 0.1 53 0.1
Region of residencel
Northeast 5,998 10.7 5,560 9.9 5,323 9.5 4,252 7.4 4,993 8.7
Midwest 5,119 7.5 4,953 7.3 4,774 7.0 4,115 6.0 4,824 7.0
South 19,707 15.9 19,273 15.5 18,982 15.1 15,566 12.3 18,728 14.7
West 7,609 9.8 7,599 9.8 7,399 9.4 6,402 8.1 7,224 9.2
U.S. dependent areas 463 12.4 463 12.9 424 11.8 310 8.4 420 11.5
Total 38,896 11.8 37,848 11.5 36,902 11.1 30,645 9.1 36,189 10.8

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data include transgender and additional gender identity persons.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at time of diagnosis of HIV infection.

Table 2a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2021—United States
American Indian/Alaska Native Asian Black/African American Hispanic/Latinoa Native Hawaiian/other Pacific Islander White Multiracial Total
No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb
Gender
Male 167 627 10,611 8,626 60 7,412 801 28,304
Female 46 93 3,540 1,159 10 1,505 201 6,554
Transgender woman/girlc 10 17 374 257 6 112 35 811
Transgender man/boyc 0 2 18 14 0 19 3 56
Additional gender identityd 0 0 12 14 0 15 3 44
Age at diagnosis (yr)
< 13 0 0.0 2 0.1 33 0.5 11 0.1 0 0.0 5 0.0 2 0.1 53 0.1
13–14 0 0.0 0 0.0 8 0.7 6 0.3 0 0.0 1 0.0 0 0.0 15 0.2
15–19 12 6.7 23 2.0 825 28.2 368 6.9 6 13.9 156 1.4 62 7.6 1,452 6.7
20–24 21 11.6 94 7.7 2,864 94.8 1,480 29.8 5 11.7 814 7.1 182 25.6 5,460 25.4
25–29 49 25.9 142 9.7 2,776 84.8 2,082 42.8 15 31.7 1,447 12.1 202 32.6 6,713 30.0
30–34 42 22.4 132 7.8 2,443 74.5 1,931 40.9 13 24.2 1,617 12.8 190 38.3 6,368 27.6
35–39 33 20.1 96 5.7 1,515 52.9 1,368 29.7 12 23.1 1,263 10.1 116 29.0 4,403 19.7
40–44 16 10.6 75 4.9 1,052 38.8 929 21.2 9 19.9 976 8.2 83 24.2 3,140 14.9
45–49 15 10.8 48 3.3 823 33.0 658 16.6 3 7.8 721 6.3 58 20.6 2,326 11.8
50–54 19 13.2 59 4.5 701 27.2 523 14.7 7 19.0 746 5.7 61 23.7 2,116 10.1
55–59 6 3.9 31 2.7 707 27.0 354 11.5 2 5.6 640 4.5 46 19.5 1,786 8.3
60–64 6 4.1 19 1.8 456 18.6 206 8.4 2 6.3 389 2.6 17 7.8 1,095 5.2
≥ 65 4 1.2 18 0.7 352 6.7 154 3.0 2 3.0 288 0.7 24 5.0 842 1.5
Transmission categorye
Male sex at birth (≥ 13 yrs at diagnosis)f
Male-to-male sexual contactg 141 573 8,879 7,757 59 5,758 688 23,855
Injection drug useh 10 14 371 299 1 679 41 1,415
Male-to-male sexual contactg
and injection drug useh
16 17 244 325 4 714 54 1,373
Heterosexual contacti 11 40 1,470 506 3 379 52 2,460
Perinatalj 0 0 8 3 0 0 0 11
Otherk 0 1 6 4 0 6 1 18
Subtotal 177 17.7 644 8.1 10,978 66.5 8,895 35.7 66 25.5 7,536 8.9 836 32.7 29,132 21.1
   Female sex at birth (≥ 13 yrs at diagnosis)f
Injection drug useh 17 6 300 161 3 553 35 1,075
Heterosexual contacti 29 85 3,207 997 7 962 169 5,456
Perinatalj 0 2 35 6 0 5 1 49
Otherk 0 1 2 0 0 2 0 5
Subtotal 46 4.4 93 1.1 3,544 19.5 1,164 4.8 10 3.9 1,522 1.8 205 7.6 6,584 4.6
   Child (< 13 yrs at diagnosis)
Perinatal 0 1 26 8 0 3 1 39
Otherk 0 1 7 3 0 2 1 14
Subtotal 0 0.0 2 0.1 33 0.5 11 0.1 0 0.0 5 0.0 2 0.1 53 0.1
Region of residencel
Northeast 5 3.8 141 3.5 1,952 30.0 1,625 18.5 4 17.2 1,094 3.0 172 16.2 4,993 8.7
Midwest 47 11.2 80 3.3 2,102 28.8 725 12.4 6 14.6 1,700 3.3 164 11.0 4,824 7.0
South 56 6.8 210 4.4 9,259 37.9 4,422 18.5 19 18.3 4,220 6.0 542 20.7 18,728 14.7
West 115 10.7 308 3.7 1,242 34.1 3,298 13.7 47 10.3 2,049 5.3 165 6.3 7,224 9.2
Total 223 9.1 739 3.8 14,555 34.8 10,070 16.1 76 12.1 9,063 4.6 1,043 13.4 35,769 10.8

Note: Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

a Hispanic/Latino persons can be of any race.
b Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data presented include transgender and additional gender identity persons.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
l Data are based on residence at time of diagnosis of HIV infection.

Table 2b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2021—United States and 6 dependent areas
American Indian/Alaska Native Asian Black/African American Hispanic/Latinoa Native Hawaiian/other Pacific Islander White Multiracial Total
No. No. No. No. No. No. No. No.
Gender
Male 167 628 10,616 8,952 60 7,417 801 28,641
Female 46 93 3,541 1,240 10 1,505 201 6,636
Transgender woman/girlb 10 17 374 258 6 112 35 812
Transgender man/boyb 0 2 18 14 0 19 3 56
Additional gender identityc 0 0 12 14 0 15 3 44
Age at diagnosis (yr)
< 13 0 2 33 11 0 5 2 53
13–14 0 0 8 6 0 1 0 15
15–19 12 23 825 376 6 156 62 1,460
20–24 21 94 2,865 1,531 5 814 182 5,512
25–29 49 143 2,776 2,160 15 1,448 202 6,793
30–34 42 132 2,444 1,973 13 1,617 190 6,411
35–39 33 96 1,515 1,412 12 1,264 116 4,448
40–44 16 75 1,052 975 9 976 83 3,186
45–49 15 48 823 690 3 722 58 2,359
50–54 19 59 703 565 7 746 61 2,160
55–59 6 31 708 373 2 641 46 1,807
60–64 6 19 457 225 2 390 17 1,116
≥ 65 4 18 352 181 2 288 24 869
Transmission categoryd
Male sex at birth (≥ 13 yrs at diagnosis)e
Male-to-male sexual contactf 141 574 8,883 8,000 59 5,762 688 24,107
Injection drug useg 10 14 373 318 1 679 41 1,436
Male-to-male sexual contactf
and injection drug useg
16 17 244 327 4 714 54 1,375
Heterosexual contacth 11 40 1,470 569 3 379 52 2,523
Perinatali 0 0 8 3 0 0 0 11
Otherj 0 1 6 4 0 6 1 18
Subtotal 177 645 10,983 9,222 66 7,541 836 29,470
   Female sex at birth (≥ 13 yrs at diagnosis)e
Injection drug useg 17 6 301 162 3 553 35 1,077
Heterosexual contacth 29 85 3,208 1,077 7 962 169 5,536
Perinatali 0 2 35 6 0 5 1 49
Otherj 0 1 2 0 0 2 0 5
Subtotal 46 93 3,545 1,245 10 1,522 205 6,666
   Child (< 13 yrs at diagnosis)
Perinatal 0 1 26 8 0 3 1 39
Otherj 0 1 7 3 0 2 1 14
Subtotal 0 2 33 11 0 5 2 53
Region of residencek
Northeast 5 141 1,952 1,625 4 1,094 172 4,993
Midwest 47 80 2,102 725 6 1,700 164 4,824
South 56 210 9,259 4,422 19 4,220 542 18,728
West 115 308 1,242 3,298 47 2,049 165 7,224
U.S. dependent areas 0 1 6 408 0 5 0 420
Total 223 740 14,561 10,478 76 9,068 1,043 36,189

Note: Numbers less than 12 should be interpreted with caution.

a Hispanic/Latino persons can be of any race.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Data include transgender and additional gender identity persons.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at time of diagnosis of HIV infection.

Table 3a. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, assigned sex at birth, and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at diagnosis (yr)
13–14 13 0.3 11 0.3 12 0.3 6 0.1 8 0.2
15–19 1,541 14.3 1,480 13.8 1,449 13.5 1,107 10.1 1,250 11.3
20–24 5,711 50.5 5,399 48.3 5,262 47.5 4,288 39.2 4,840 44.1
25–29 6,741 56.7 6,738 56.1 6,443 53.6 5,310 45.9 5,867 51.6
30–34 4,667 42.1 4,713 42.1 4,690 41.2 4,391 37.9 5,411 46.3
35–39 3,338 31.5 3,265 30.3 3,202 29.4 2,693 24.0 3,475 30.9
40–44 2,241 23.1 2,175 22.2 2,189 22.1 1,911 18.4 2,368 22.4
45–49 2,165 20.9 2,040 19.9 1,885 18.7 1,493 14.7 1,676 17.0
50–54 1,976 18.8 1,780 17.3 1,680 16.7 1,379 13.3 1,543 14.8
55–59 1,311 12.3 1,286 12.1 1,322 12.4 1,139 10.5 1,283 12.1
60–64 751 7.9 722 7.4 758 7.7 614 6.0 809 7.8
≥ 65 612 2.7 633 2.7 606 2.5 515 2.1 602 2.4
Race/ethnicity
American Indian/Alaska Native 150 15.7 140 14.5 150 15.4 149 15.0 177 17.7
Asian 797 10.9 742 9.9 624 8.2 527 6.7 644 8.1
Black/African American 11,861 75.4 11,621 73.1 11,476 71.5 9,744 59.5 10,978 66.5
Hispanic/Latinoc 8,814 38.9 8,729 37.7 8,673 36.7 7,115 29.1 8,895 35.7
Native Hawaiian/other Pacific Islander 39 16.5 53 21.9 52 21.1 49 19.3 66 25.5
White 8,128 9.7 7,865 9.4 7,473 8.9 6,445 7.6 7,536 8.9
Multiracial 1,278 58.0 1,092 47.9 1,050 44.5 817 33.1 836 32.7
Region of residenced
Northeast 4,662 20.2 4,332 18.7 4,161 18.0 3,362 14.0 3,942 16.5
Midwest 4,155 14.9 4,016 14.3 3,798 13.5 3,366 11.8 3,922 13.7
South 15,580 31.1 15,302 30.2 15,133 29.6 12,552 24.2 14,996 28.7
West 6,670 20.9 6,592 20.4 6,406 19.7 5,566 16.9 6,272 18.9
Subtotal 31,067 23.3 30,242 22.6 29,498 21.9 24,846 18.1 29,132 21.1
Female sex at birthb
Age at diagnosis (yr)
13–14 12 0.3 9 0.2 9 0.2 6 0.1 7 0.2
15–19 250 2.4 242 2.3 203 2.0 157 1.5 202 1.9
20–24 770 7.2 724 6.8 725 6.9 561 5.3 620 5.9
25–29 979 8.5 944 8.2 939 8.2 770 6.9 846 7.7
30–34 1,013 9.3 951 8.7 955 8.6 808 7.1 957 8.4
35–39 916 8.6 921 8.6 900 8.3 707 6.4 928 8.4
40–44 740 7.5 789 8.0 757 7.6 563 5.5 772 7.3
45–49 761 7.2 719 6.9 686 6.7 551 5.4 650 6.6
50–54 661 6.1 655 6.2 623 6.0 449 4.3 573 5.5
55–59 558 4.9 538 4.8 515 4.6 419 3.7 503 4.6
60–64 331 3.2 320 3.0 348 3.2 265 2.5 286 2.6
≥ 65 270 1.0 245 0.8 263 0.9 173 0.6 240 0.8
Race/ethnicity
American Indian/Alaska Native 43 4.3 30 3.0 43 4.2 40 3.9 46 4.4
Asian 114 1.4 102 1.2 98 1.1 83 1.0 93 1.1
Black/African American 4,246 24.1 3,972 22.3 3,820 21.3 2,899 16.0 3,544 19.5
Hispanic/Latinoc 1,181 5.3 1,192 5.2 1,178 5.0 922 3.9 1,164 4.8
Native Hawaiian/other Pacific Islander 7 3.0 4 1.7 7 2.9 14 5.6 10 3.9
White 1,415 1.6 1,458 1.7 1,512 1.7 1,287 1.5 1,522 1.8
Multiracial 255 10.9 299 12.3 265 10.6 184 7.1 205 7.6
Region of residenced
Northeast 1,326 5.4 1,220 4.9 1,156 4.7 879 3.5 1,046 4.2
Midwest 944 3.2 925 3.2 969 3.3 740 2.5 893 3.0
South 4,065 7.7 3,923 7.3 3,817 7.1 2,985 5.5 3,707 6.8
West 926 2.9 989 3.0 981 3.0 825 2.5 938 2.8
Subtotal 7,261 5.2 7,057 5.0 6,923 4.9 5,429 3.8 6,584 4.6
Total 38,328 14.1 37,299 13.6 36,421 13.2 30,275 10.9 35,716 12.7

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population.
b Data include transgender and additional gender identity persons.
c Hispanic/Latino persons can be of any race.
d Data are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥ 13 years, by year of diagnosis, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at diagnosis (yr)
13–14 13 0.3 11 0.3 12 0.3 6 0.1 8 0.2
15–19 1,551 14.2 1,496 13.7 1,455 13.4 1,115 10.0 1,256 11.3
20–24 5,772 50.4 5,455 48.3 5,315 47.5 4,327 39.1 4,883 44.0
25–29 6,792 56.5 6,808 56.1 6,498 53.5 5,350 45.7 5,944 51.7
30–34 4,721 42.2 4,766 42.2 4,739 41.3 4,428 37.9 5,449 46.2
35–39 3,378 31.6 3,297 30.3 3,236 29.4 2,728 24.1 3,507 30.9
40–44 2,270 23.1 2,208 22.3 2,215 22.1 1,932 18.4 2,401 22.4
45–49 2,192 20.9 2,072 20.0 1,912 18.8 1,511 14.7 1,702 17.0
50–54 2,014 19.0 1,818 17.5 1,704 16.7 1,405 13.4 1,576 14.9
55–59 1,335 12.4 1,307 12.1 1,347 12.5 1,158 10.6 1,301 12.1
60–64 769 8.0 737 7.5 779 7.8 628 6.1 823 7.9
≥ 65 629 2.8 649 2.8 627 2.6 522 2.1 620 2.4
Race/ethnicity
American Indian/Alaska Native 150 140 150 149 177
Asian 800 746 631 527 645
Black/African American 11,863 11,632 11,481 9,749 10,983
Hispanic/Latinoc 9,171 9,087 8,993 7,372 9,222
Native Hawaiian/other Pacific Islander 42 55 55 50 66
White 8,131 7,871 7,479 6,446 7,541
Multiracial 1,279 1,093 1,050 817 836
Region of residenced
Northeast 4,662 20.2 4,332 18.7 4,161 18.0 3,362 14.0 3,942 16.5
Midwest 4,155 14.9 4,016 14.3 3,798 13.5 3,366 11.8 3,922 13.7
South 15,580 31.1 15,302 30.2 15,133 29.6 12,552 24.2 14,996 28.7
West 6,670 20.9 6,592 20.4 6,406 19.7 5,566 16.9 6,272 18.9
U.S. dependent areas 369 24.4 382 26.0 341 23.1 264 17.4 338 22.2
Subtotal 31,436 23.3 30,624 22.6 29,839 21.9 25,110 18.1 29,470 21.1
Female sex at birthb
Age at diagnosis (yr)
13–14 12 0.3 9 0.2 9 0.2 6 0.1 7 0.2
15–19 253 2.4 244 2.3 203 1.9 157 1.5 204 1.9
20–24 775 7.1 733 6.8 730 6.8 566 5.3 629 5.9
25–29 990 8.5 951 8.2 944 8.1 774 6.8 849 7.6
30–34 1,020 9.3 957 8.7 964 8.6 809 7.1 962 8.3
35–39 928 8.7 925 8.5 906 8.3 710 6.4 941 8.4
40–44 747 7.5 797 8.0 769 7.6 570 5.5 785 7.4
45–49 776 7.3 733 6.9 697 6.7 556 5.4 657 6.6
50–54 673 6.1 666 6.2 630 6.0 454 4.3 584 5.5
55–59 571 5.0 546 4.8 528 4.6 427 3.8 506 4.6
60–64 336 3.2 325 3.0 354 3.3 268 2.5 293 2.7
≥ 65 274 1.0 252 0.9 272 0.9 178 0.6 249 0.8
Race/ethnicity
American Indian/Alaska Native 43 30 43 40 46
Asian 114 102 98 83 93
Black/African American 4,249 3,973 3,823 2,901 3,545
Hispanic/Latinoc 1,270 1,272 1,257 966 1,245
Native Hawaiian/other Pacific Islander 7 4 8 14 10
White 1,416 1,458 1,512 1,287 1,522
Multiracial 256 299 265 184 205
Region of residenced
Northeast 1,326 5.4 1,220 4.9 1,156 4.7 879 3.5 1,046 4.2
Midwest 944 3.2 925 3.2 969 3.3 740 2.5 893 3.0
South 4,065 7.7 3,923 7.3 3,817 7.1 2,985 5.5 3,707 6.8
West 926 2.9 989 3.0 981 3.0 825 2.5 938 2.8
U.S. dependent areas 94 5.6 81 5.0 83 5.0 46 2.7 82 4.8
Subtotal 7,355 5.2 7,138 5.0 7,006 4.9 5,475 3.8 6,666 4.6
Total 38,791 14.1 37,762 13.6 36,845 13.2 30,585 10.8 36,136 12.7

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
b Data include transgender and additional gender identity persons.
c Hispanic/Latino persons can be of any race.
d Data are based on residence at time of diagnosis of HIV infection.

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at diagnosis (yr)
13–14 0 0 0 0 1
15–19 67 48 44 34 58
20–24 164 175 180 156 227
25–29 174 195 177 212 172
30–34 114 98 138 127 167
35–39 59 72 63 49 77
40–44 31 33 42 35 51
45–49 22 22 19 32 25
50–54 8 6 16 19 12
55–59 7 6 8 6 12
60–64 5 4 4 5 8
≥ 65 0 2 1 1 1
Race/ethnicity
American Indian/Alaska Native 2 9 5 8 10
Asian 19 11 11 14 17
Black/African American 324 317 341 327 374
Hispanic/Latinob 196 219 226 220 257
Native Hawaiian/other Pacific Islander 4 3 5 3 6
White 80 69 79 73 112
Multiracial 26 33 25 31 35
Exposure categoryc
Sexual contactd 592 596 616 611 716
Injection drug usee 4 4 2 1 3
Sexual contactd
and injection drug usee
40 53 58 44 56
Otherf 15 8 16 20 36
Region of residenceg
Northeast 104 117 105 111 110
Midwest 108 108 96 102 139
South 294 290 310 298 352
West 145 146 181 165 210
Subtotal 651 661 692 676 811
Transgender mana
Age at diagnosis (yr)
13–14 0 0 0 0 1
15–19 3 2 0 1 6
20–24 7 9 11 12 8
25–29 16 18 18 10 17
30–34 1 9 13 8 13
35–39 2 4 1 6 6
40–44 0 4 0 2 2
45–49 2 1 2 1 0
50–54 0 1 0 1 1
55–59 1 0 0 0 1
60–64 0 0 0 0 0
≥ 65 0 0 0 0 1
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asian 2 0 1 0 2
Black/African American 11 17 17 10 18
Hispanic/Latinob 6 11 13 11 14
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 10 18 9 15 19
Multiracial 3 2 5 5 3
Exposure categoryc
Sexual contactd 27 40 35 30 47
Injection drug usee 1 2 1 1 0
Sexual contactd
and injection drug usee
1 3 3 5 1
Otherf 3 3 6 5 8
Region of residenceg
Northeast 5 7 6 9 9
Midwest 8 7 6 2 10
South 12 16 18 24 22
West 7 18 15 6 15
Subtotal 32 48 45 41 56
Additional gender identityh
Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 4 5 3 3
20–24 4 7 13 7 22
25–29 3 4 7 8 7
30–34 3 2 4 1 5
35–39 5 1 2 2 2
40–44 0 0 0 1 1
45–49 2 1 0 1 2
50–54 0 0 1 0 2
55–59 0 0 0 0 0
60–64 0 0 0 0 0
≥ 65 0 0 0 0 0
Race/ethnicity
American Indian/Alaska Native 0 1 0 0 0
Asian 1 2 0 1 0
Black/African American 7 7 11 10 12
Hispanic/Latinob 7 4 7 5 14
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 3 3 9 6 15
Multiracial 0 2 5 1 3
Exposure categoryc
Sexual contactd 16 19 29 20 38
Injection drug usee 0 0 0 0 0
Sexual contactd
and injection drug usee
1 0 2 1 5
Otherf 1 0 1 2 1
Region of residenceg
Northeast 9 8 9 2 12
Midwest 3 4 10 6 8
South 6 5 9 7 9
West 0 2 4 8 15
Subtotal 18 19 32 23 44
Total 701 728 769 740 911

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Hispanic/Latino persons can be of any race.
c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
g Data are based on residence at time of diagnosis of HIV infection.
h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥ 13 years, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at diagnosis (yr)
13–14 0 0 0 0 1
15–19 67 48 44 34 58
20–24 165 176 181 158 227
25–29 175 196 178 212 172
30–34 114 99 138 128 167
35–39 59 73 63 49 77
40–44 31 33 42 35 52
45–49 22 22 19 32 25
50–54 8 6 16 19 12
55–59 7 6 8 6 12
60–64 5 4 4 5 8
≥ 65 0 2 1 1 1
Race/ethnicity
American Indian/Alaska Native 2 9 5 8 10
Asian 19 11 11 14 17
Black/African American 324 317 341 327 374
Hispanic/Latinob 198 223 228 223 258
Native Hawaiian/other Pacific Islander 4 3 5 3 6
White 80 69 79 73 112
Multiracial 26 33 25 31 35
Exposure categoryc
Sexual contactd 594 600 618 614 717
Injection drug usee 4 4 2 1 3
Sexual contactd
and injection drug usee
40 53 58 44 56
Otherf 15 8 16 20 36
Region of residenceg
Northeast 104 117 105 111 110
Midwest 108 108 96 102 139
South 294 290 310 298 352
West 145 146 181 165 210
US dependent areas 2 4 2 3 1
Subtotal 653 665 694 679 812
Transgender mana
Age at diagnosis (yr)
13–14 0 0 0 0 1
15–19 3 2 0 1 6
20–24 7 9 11 12 8
25–29 16 18 18 10 17
30–34 1 9 13 8 13
35–39 2 4 1 6 6
40–44 0 4 0 2 2
45–49 2 1 2 1 0
50–54 0 1 0 1 1
55–59 1 0 0 0 1
60–64 0 0 0 0 0
≥ 65 0 0 0 0 1
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asian 2 0 1 0 2
Black/African American 11 17 17 10 18
Hispanic/Latinob 6 11 13 11 14
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 10 18 9 15 19
Multiracial 3 2 5 5 3
Exposure categoryc
Sexual contactd 27 40 35 30 47
Injection drug usee 1 2 1 1 0
Sexual contactd
and injection drug usee
1 3 3 5 1
Otherf 3 3 6 5 8
Region of residenceg
Northeast 5 7 6 9 9
Midwest 8 7 6 2 10
South 12 16 18 24 22
West 7 18 15 6 15
US dependent areas 0 0 0 0 0
Subtotal 32 48 45 41 56
Additional gender identityh
Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 4 5 3 3
20–24 4 7 13 7 22
25–29 3 4 7 8 7
30–34 3 2 4 1 5
35–39 5 1 2 2 2
40–44 0 0 0 1 1
45–49 2 1 0 1 2
50–54 0 0 1 0 2
55–59 0 0 0 0 0
60–64 0 0 0 0 0
≥ 65 0 0 0 0 0
Race/ethnicity
American Indian/Alaska Native 0 1 0 0 0
Asian 1 2 0 1 0
Black/African American 7 7 11 10 12
Hispanic/Latinob 7 4 7 5 14
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 3 3 9 6 15
Multiracial 0 2 5 1 3
Exposure categoryc
Sexual contactd 16 19 29 20 38
Injection drug usee 0 0 0 0 0
Sexual contactd
and injection drug usee
1 0 2 1 5
Otherf 1 0 1 2 1
Region of residenceg
Northeast 9 8 9 2 12
Midwest 3 4 10 6 8
South 6 5 9 7 9
West 0 2 4 8 15
US dependent areas 0 0 0 0 0
Subtotal 18 19 32 23 44
Total 703 732 771 743 912

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Hispanic/Latino persons can be of any race.
c Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
g Data are based on residence at time of diagnosis of HIV infection.
h Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 5a. Diagnoses of HIV infection among males, based on assigned sex at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2017–2021—United States
Male-to-male sexual contact Male-to-male sexual contact and injection drug use
2017 2018 2019 2020 (COVID-19 Pandemic) 2021 2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 2 7 6 5 10 0 0 0 0 0
20–24 19 24 25 19 19 3 2 3 5 1
25–29 29 21 25 25 32 5 7 5 5 1
30–34 15 19 15 18 26 6 4 1 3 6
35–39 15 8 18 13 21 0 2 3 5 4
40–44 10 7 6 12 10 2 1 0 2 1
45–49 6 7 7 6 6 1 2 1 0 1
50–54 8 6 7 10 8 0 0 1 1 2
55–59 2 3 3 5 3 0 0 0 0 0
60–64 2 0 1 1 5 1 0 0 0 0
≥ 65 1 3 0 2 2 1 0 0 0 0
Region of residencea
Northeast 2 4 3 5 4 0 0 0 0 0
Midwest 10 13 8 9 19 3 4 1 5 6
South 23 16 37 33 41 9 2 3 0 1
West 73 71 65 70 76 6 13 10 15 8
Total 108 103 113 117 141 18 19 14 21 16
Asian
Age at diagnosis (yr)
13–14 0 1 0 0 0 0 0 0 0 0
15–19 25 23 19 17 21 0 0 0 0 0
20–24 147 105 94 58 82 2 0 2 1 1
25–29 151 163 126 120 122 4 5 3 4 4
30–34 111 117 93 89 113 6 2 6 3 4
35–39 88 71 73 49 72 1 3 1 0 4
40–44 74 62 41 45 47 0 1 1 2 1
45–49 64 57 51 40 39 2 0 1 0 1
50–54 34 22 34 22 39 0 0 0 0 0
55–59 21 21 16 13 23 0 0 0 0 1
60–64 10 11 8 11 8 0 0 0 0 0
≥ 65 7 10 8 9 6 0 0 0 0 0
Region of residencea
Northeast 127 121 99 71 109 2 1 2 0 2
Midwest 73 65 53 53 56 0 0 1 1 3
South 153 169 140 100 151 1 2 4 1 4
West 380 307 270 247 256 12 9 7 10 8
Total 733 661 563 472 573 15 12 14 12 17
Black/African American
Age at diagnosis (yr)
13–14 4 7 7 2 2 0 1 0 0 0
15–19 853 808 793 604 685 12 10 10 12 9
20–24 2,512 2,409 2,378 2,072 2,343 45 52 41 41 30
25–29 2,459 2,486 2,335 1,967 2,067 75 84 87 58 50
30–34 1,334 1,266 1,424 1,447 1,636 51 50 65 53 62
35–39 752 742 741 655 778 37 29 39 26 37
40–44 434 447 456 384 423 21 18 21 16 24
45–49 351 352 333 266 288 14 12 17 8 14
50–54 324 311 283 236 232 25 17 18 6 6
55–59 205 203 204 194 228 11 9 9 7 6
60–64 111 99 111 93 122 5 6 6 3 3
≥ 65 66 76 81 54 75 5 4 2 2 2
Region of residencea
Northeast 1,140 1,073 1,112 923 1,007 38 53 38 34 36
Midwest 1,500 1,458 1,408 1,304 1,393 50 54 44 37 41
South 5,955 5,853 5,835 5,033 5,659 161 142 178 119 131
West 811 820 790 714 820 54 43 55 41 36
Total 9,405 9,205 9,145 7,973 8,879 303 292 314 232 244
Hispanic/Latinob
Age at diagnosis (yr)
13–14 5 0 2 3 3 0 0 0 0 0
15–19 339 324 363 259 312 11 12 8 7 7
20–24 1,402 1,385 1,407 1,067 1,275 68 75 70 38 46
25–29 1,770 1,788 1,744 1,440 1,741 99 114 101 88 79
30–34 1,345 1,317 1,299 1,201 1,577 74 61 71 61 71
35–39 925 904 899 736 1,031 53 48 63 36 46
40–44 593 554 588 521 655 24 28 38 21 31
45–49 517 493 449 340 440 20 20 25 20 15
50–54 343 329 351 285 330 17 17 22 11 16
55–59 172 189 179 185 204 8 3 11 5 8
60–64 71 88 91 82 118 4 5 3 7 5
≥ 65 76 68 70 54 73 2 3 3 2 2
Region of residencea
Northeast 1,300 1,177 1,172 939 1,124 44 59 62 31 34
Midwest 519 523 532 413 587 30 33 34 19 16
South 3,224 3,151 3,135 2,560 3,438 132 121 156 112 116
West 2,514 2,587 2,601 2,258 2,608 174 172 162 133 160
Total 7,556 7,438 7,441 6,170 7,757 379 385 414 295 325
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 3 1 2 5 0 0 0 1 0
20–24 7 5 6 6 3 0 2 0 0 1
25–29 7 9 16 10 15 1 2 0 1 0
30–34 7 10 9 7 9 0 1 1 1 2
35–39 2 8 7 6 10 1 0 1 1 0
40–44 5 2 4 6 7 0 0 0 0 0
45–49 1 2 0 1 3 0 0 0 1 0
50–54 1 1 3 2 4 0 0 0 0 0
55–59 0 4 1 1 1 0 0 0 0 0
60–64 0 1 1 0 2 0 0 0 0 0
≥ 65 0 1 0 0 1 0 0 0 0 0
Region of residencea
Northeast 2 2 1 3 2 0 0 0 0 0
Midwest 3 1 4 3 6 0 0 0 1 0
South 6 8 10 6 16 0 0 0 0 0
West 21 34 33 28 35 2 5 2 4 3
Total 31 45 48 41 59 2 5 2 5 4
White
Age at diagnosis (yr)
13–14 1 0 1 0 0 0 0 0 0 0
15–19 160 166 129 119 106 12 11 13 3 3
20–24 905 782 707 583 603 91 71 81 54 52
25–29 1,181 1,099 1,076 896 1,006 175 188 167 126 119
30–34 865 942 863 826 1,009 128 147 147 112 173
35–39 718 650 648 525 718 100 122 116 108 120
40–44 489 509 448 434 547 64 59 67 52 100
45–49 606 546 461 395 426 62 51 55 46 55
50–54 669 530 499 435 465 38 44 38 32 42
55–59 436 429 459 404 434 24 27 33 24 21
60–64 243 248 236 202 263 17 6 14 10 19
≥ 65 181 213 184 181 180 11 7 10 4 11
Region of residencea
Northeast 825 745 687 560 668 79 80 65 72 82
Midwest 1,202 1,082 959 923 1,081 107 136 150 100 142
South 2,795 2,741 2,605 2,201 2,620 319 302 309 225 284
West 1,632 1,545 1,459 1,318 1,389 217 217 220 174 207
Total 6,454 6,113 5,710 5,002 5,758 721 734 742 570 714
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 64 48 51 44 54 3 2 2 0 0
20–24 245 221 189 138 149 13 12 6 9 6
25–29 272 218 218 168 145 15 30 22 13 14
30–34 162 138 136 102 125 14 14 27 6 16
35–39 94 95 83 74 65 14 13 8 7 8
40–44 59 55 58 51 46 5 2 11 8 1
45–49 59 47 40 43 31 5 5 1 5 4
50–54 59 36 20 31 32 6 4 2 2 1
55–59 24 18 39 16 23 4 0 1 0 2
60–64 13 12 11 8 6 0 0 1 1 0
≥ 65 7 11 8 11 13 0 1 1 0 1
Region of residencea
Northeast 177 151 150 108 111 12 11 8 5 6
Midwest 167 124 101 100 103 11 16 14 11 16
South 504 452 436 354 360 40 30 43 23 20
West 209 172 164 124 115 17 28 16 12 12
Total 1,057 898 852 685 688 79 84 81 51 54
Total
Age at diagnosis (yr)
13–14 10 8 10 4 5 0 1 0 0 1
15–19 1,444 1,377 1,362 1,049 1,193 39 37 34 23 19
20–24 5,237 4,931 4,805 3,944 4,473 222 214 203 147 137
25–29 5,870 5,784 5,540 4,623 5,128 372 430 384 295 268
30–34 3,838 3,807 3,838 3,689 4,496 278 280 318 240 334
35–39 2,592 2,479 2,468 2,059 2,694 206 217 231 182 218
40–44 1,665 1,635 1,600 1,453 1,735 116 109 138 102 159
45–49 1,605 1,505 1,341 1,090 1,232 105 91 99 80 91
50–54 1,438 1,235 1,197 1,023 1,109 85 82 80 53 67
55–59 860 865 900 818 914 47 40 54 36 38
60–64 450 458 459 397 525 28 18 25 20 28
≥ 65 338 380 350 311 350 19 14 17 8 16
Region of residencea
Northeast 3,572 3,273 3,225 2,609 3,025 175 204 175 142 160
Midwest 3,474 3,266 3,064 2,805 3,244 201 243 244 176 225
South 12,660 12,389 12,199 10,288 12,286 661 598 691 480 555
West 5,639 5,536 5,382 4,758 5,300 480 487 472 387 434
Total 25,345 24,464 23,870 20,460 23,855 1,517 1,531 1,581 1,185 1,373

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

a Data are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 5b. Diagnoses of HIV infection among males, based on assigned sex at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2017–2021—United States and 6 dependent areas
Male-to-male sexual contact Male-to-male sexual contact and injection drug use
2017 2018 2019 2020 (COVID-19 Pandemic) 2021 2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 2 7 6 5 10 0 0 0 0 0
20–24 19 24 25 19 19 3 2 3 5 1
25–29 29 21 25 25 32 5 7 5 5 1
30–34 15 19 15 18 26 6 4 1 3 6
35–39 15 8 18 13 21 0 2 3 5 4
40–44 10 7 6 12 10 2 1 0 2 1
45–49 6 7 7 6 6 1 2 1 0 1
50–54 8 6 7 10 8 0 0 1 1 2
55–59 2 3 3 5 3 0 0 0 0 0
60–64 2 0 1 1 5 1 0 0 0 0
≥ 65 1 3 0 2 2 1 0 0 0 0
Region of residencea
Northeast 2 4 3 5 4 0 0 0 0 0
Midwest 10 13 8 9 19 3 4 1 5 6
South 23 16 37 33 41 9 2 3 0 1
West 73 71 65 70 76 6 13 10 15 8
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 108 103 113 117 141 18 19 14 21 16
Asian
Age at diagnosis (yr)
13–14 0 1 0 0 0 0 0 0 0 0
15–19 25 23 19 17 21 0 0 0 0 0
20–24 147 105 94 58 82 2 0 2 1 1
25–29 151 164 129 120 123 4 5 4 4 4
30–34 113 119 94 89 113 6 2 6 3 4
35–39 89 71 74 49 72 1 3 1 0 4
40–44 74 62 41 45 47 0 1 1 2 1
45–49 64 57 51 40 39 2 0 1 0 1
50–54 34 22 35 22 39 0 0 0 0 0
55–59 21 21 16 13 23 0 0 0 0 1
60–64 10 11 8 11 8 0 0 0 0 0
≥ 65 7 10 8 9 6 0 0 0 0 0
Region of residencea
Northeast 127 121 99 71 109 2 1 2 0 2
Midwest 73 65 53 53 56 0 0 1 1 3
South 153 169 140 100 151 1 2 4 1 4
West 380 307 270 247 256 12 9 7 10 8
U.S. dependent areas 3 4 5 0 1 0 0 1 0 0
Total 736 665 568 472 574 15 12 15 12 17
Black/African American
Age at diagnosis (yr)
13–14 4 7 7 2 2 0 1 0 0 0
15–19 853 808 793 606 685 12 10 10 12 9
20–24 2,512 2,410 2,379 2,072 2,344 45 52 41 41 30
25–29 2,459 2,488 2,336 1,967 2,067 75 84 87 58 50
30–34 1,334 1,267 1,424 1,447 1,637 51 50 65 53 62
35–39 752 742 741 655 778 37 29 39 26 37
40–44 435 447 456 384 423 21 18 21 16 24
45–49 351 352 333 266 288 14 12 17 8 14
50–54 324 311 283 237 232 25 17 18 6 6
55–59 205 203 204 194 229 11 9 9 7 6
60–64 111 99 111 93 122 5 6 6 3 3
≥ 65 66 76 81 54 75 5 4 2 2 2
Region of residencea
Northeast 1,140 1,073 1,112 923 1,007 38 53 38 34 36
Midwest 1,500 1,458 1,408 1,304 1,393 50 54 44 37 41
South 5,955 5,853 5,835 5,033 5,659 161 142 178 119 131
West 811 820 790 714 820 54 43 55 41 36
U.S. dependent areas 2 4 2 3 3 0 0 0 0 0
Total 9,407 9,209 9,147 7,976 8,883 303 292 314 232 244
Hispanic/Latinob
Age at diagnosis (yr)
13–14 5 0 2 3 3 0 0 0 0 0
15–19 347 339 369 265 314 11 12 8 7 8
20–24 1,451 1,437 1,453 1,103 1,316 70 76 73 39 46
25–29 1,811 1,841 1,790 1,474 1,812 103 117 102 90 79
30–34 1,382 1,353 1,336 1,231 1,609 75 64 73 61 71
35–39 948 926 923 763 1,055 55 49 64 37 46
40–44 609 578 601 533 677 24 28 38 21 32
45–49 534 516 462 352 453 22 20 26 20 15
50–54 365 346 366 304 349 17 17 22 11 16
55–59 183 199 191 193 213 8 4 12 5 8
60–64 75 96 100 88 123 4 6 4 7 5
≥ 65 80 71 74 56 77 2 4 4 2 2
Region of residencea
Northeast 1,300 1,177 1,172 939 1,124 44 59 62 31 34
Midwest 519 523 532 413 587 30 33 34 19 16
South 3,224 3,151 3,135 2,560 3,438 132 121 156 112 116
West 2,514 2,587 2,601 2,258 2,608 174 172 162 133 160
U.S. dependent areas 232 263 226 195 243 12 11 11 5 2
Total 7,788 7,701 7,666 6,366 8,000 391 397 425 299 327
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 3 1 2 5 0 0 0 1 0
20–24 7 5 6 6 3 0 2 0 0 1
25–29 7 9 16 10 15 1 2 1 1 0
30–34 7 10 9 8 9 0 1 1 1 2
35–39 2 9 7 6 10 1 0 1 1 0
40–44 5 2 5 6 7 0 0 0 0 0
45–49 1 2 0 1 3 0 0 0 1 0
50–54 2 1 4 2 4 0 0 0 0 0
55–59 1 4 1 1 1 0 0 0 0 0
60–64 0 1 1 0 2 0 0 0 0 0
≥ 65 0 1 0 0 1 0 0 0 0 0
Region of residencea
Northeast 2 2 1 3 2 0 0 0 0 0
Midwest 3 1 4 3 6 0 0 0 1 0
South 6 8 10 6 16 0 0 0 0 0
West 21 34 33 28 35 2 5 2 4 3
U.S. dependent areas 2 2 2 1 0 0 0 1 0 0
Total 33 46 50 42 59 2 5 3 5 4
White
Age at diagnosis (yr)
13–14 1 0 1 0 0 0 0 0 0 0
15–19 160 166 129 119 106 12 11 13 3 3
20–24 905 782 707 583 603 91 71 81 54 52
25–29 1,181 1,099 1,076 896 1,007 175 188 167 126 119
30–34 865 942 865 826 1,009 128 147 147 112 173
35–39 720 651 648 525 719 100 122 116 108 120
40–44 489 510 448 434 547 64 59 67 52 100
45–49 606 547 461 396 427 62 51 55 46 55
50–54 670 532 500 435 465 38 44 38 32 42
55–59 436 430 459 404 435 24 27 33 24 21
60–64 243 248 237 202 264 17 6 14 10 19
≥ 65 181 213 185 181 180 11 7 10 4 11
Region of residencea
Northeast 825 745 687 560 668 79 80 65 72 82
Midwest 1,202 1,082 959 923 1,081 107 136 150 100 142
South 2,795 2,741 2,605 2,201 2,620 319 302 309 225 284
West 1,632 1,545 1,459 1,318 1,389 217 217 220 174 207
U.S. dependent areas 3 6 4 1 5 0 0 0 0 0
Total 6,457 6,119 5,714 5,002 5,762 721 734 742 570 714
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 64 48 51 44 54 3 2 2 0 0
20–24 245 221 189 138 149 13 12 6 9 6
25–29 272 218 218 168 145 15 30 22 13 14
30–34 162 138 136 102 125 14 14 27 6 16
35–39 94 95 83 74 65 14 13 8 7 8
40–44 59 55 58 51 46 5 2 11 8 1
45–49 59 47 40 43 31 5 5 1 5 4
50–54 59 36 20 31 32 6 4 2 2 1
55–59 24 18 39 16 23 4 0 1 0 2
60–64 13 12 11 8 6 0 0 1 1 0
≥ 65 7 11 8 11 13 0 1 1 0 1
Region of residencea
Northeast 177 151 150 108 111 12 11 8 5 6
Midwest 167 124 101 100 103 11 16 14 11 16
South 504 452 436 354 360 40 30 43 23 20
West 209 172 164 124 115 17 28 16 12 12
U.S. dependent areas 1 0 0 0 0 0 0 0 0 0
Total 1,058 898 852 685 688 79 84 81 51 54
Total
Age at diagnosis (yr)
13–14 10 8 10 4 5 0 1 0 0 1
15–19 1,452 1,392 1,368 1,057 1,195 39 37 34 23 20
20–24 5,286 4,983 4,852 3,980 4,515 224 215 206 148 137
25–29 5,910 5,840 5,590 4,658 5,201 376 433 387 297 268
30–34 3,877 3,846 3,878 3,721 4,529 279 283 320 240 334
35–39 2,619 2,503 2,493 2,086 2,719 208 218 232 183 218
40–44 1,682 1,661 1,615 1,466 1,757 116 109 138 102 159
45–49 1,622 1,529 1,354 1,103 1,246 107 91 100 81 91
50–54 1,461 1,255 1,214 1,042 1,129 85 82 80 53 67
55–59 872 878 913 827 925 47 41 55 36 38
60–64 454 466 469 403 530 28 19 25 20 28
≥ 65 343 383 356 313 355 19 15 18 8 16
Region of residencea
Northeast 3,572 3,273 3,225 2,609 3,025 175 204 175 142 160
Midwest 3,474 3,266 3,064 2,805 3,244 201 243 244 176 225
South 12,660 12,389 12,199 10,288 12,286 661 598 691 480 555
West 5,639 5,536 5,382 4,758 5,300 480 487 472 387 434
U.S. dependent areas 242 278 240 200 252 12 11 13 5 2
Total 25,587 24,742 24,110 20,660 24,107 1,529 1,542 1,594 1,190 1,375

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

a Data are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States
Male sex at birth Female sex at birth
2017 2018 2019 2020 (COVID-19 Pandemic) 2021 2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 0 0 0 0 0 0 0 1
20–24 0 0 2 1 0 1 0 2 0 1
25–29 6 1 0 0 3 2 3 1 5 5
30–34 3 3 2 4 1 2 2 2 4 4
35–39 0 0 3 1 0 2 4 6 4 2
40–44 1 0 3 0 2 2 1 2 1 0
45–49 0 1 1 0 2 2 2 1 2 2
50–54 3 2 1 2 0 3 2 2 0 3
55–59 0 0 0 0 0 0 1 0 1 1
60–64 1 0 0 0 0 1 1 0 0 0
≥ 65 1 0 0 0 0 1 0 1 0 0
Region of residencea
Northeast 1 0 0 0 0 1 0 0 0 0
Midwest 2 3 3 2 3 1 3 5 8 6
South 2 1 3 4 3 4 6 6 1 1
West 11 6 8 2 4 9 6 7 8 10
Total 17 9 14 9 10 16 15 18 17 17
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 1 0 0 0 0 0 0 0 0
25–29 1 0 1 1 0 2 0 0 0 2
30–34 1 3 0 2 2 0 2 2 2 0
35–39 1 0 3 1 2 1 1 1 1 0
40–44 3 2 2 2 2 0 0 1 0 1
45–49 2 2 2 2 2 0 0 1 0 0
50–54 1 1 3 2 2 1 0 0 1 1
55–59 0 1 1 0 1 0 1 0 0 0
60–64 0 1 1 1 2 1 1 0 0 0
≥ 65 0 1 0 1 0 0 0 0 0 0
Region of residencea
Northeast 4 5 3 2 2 1 2 2 1 1
Midwest 0 1 3 2 4 0 0 0 0 1
South 2 4 2 1 1 1 2 1 2 2
West 4 1 6 8 6 3 2 3 2 2
Total 10 11 14 13 14 5 5 6 5 6
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 5 4 3 2 2 12 9 7 8 5
20–24 19 22 20 18 25 35 23 32 18 24
25–29 34 45 50 33 33 36 30 45 37 36
30–34 49 43 58 42 50 39 42 42 36 38
35–39 44 53 42 33 48 39 36 42 31 37
40–44 30 35 39 28 43 42 29 39 20 33
45–49 42 41 31 30 30 41 32 37 29 29
50–54 42 49 37 29 33 40 40 34 25 29
55–59 55 50 39 37 43 33 38 33 30 31
60–64 32 36 41 23 34 25 24 27 18 19
≥ 65 33 35 32 28 31 19 16 20 10 19
Region of residencea
Northeast 120 118 107 85 94 95 76 97 52 68
Midwest 61 57 52 43 47 60 48 50 43 53
South 173 195 190 149 191 172 158 171 132 147
West 30 43 41 24 39 35 35 40 34 32
Total 385 413 389 301 371 361 318 358 260 300
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 1 0
15–19 4 3 1 2 1 5 2 6 3 3
20–24 22 24 17 14 21 20 24 19 11 12
25–29 40 30 46 39 38 21 21 23 19 25
30–34 59 64 46 34 60 35 27 22 30 26
35–39 45 49 48 39 46 24 29 34 26 26
40–44 42 35 35 40 33 18 16 13 14 18
45–49 38 35 23 26 30 15 20 17 11 13
50–54 40 38 28 24 26 13 15 18 9 14
55–59 23 26 25 14 20 9 10 10 10 12
60–64 12 15 13 14 12 7 9 7 9 6
≥ 65 12 8 13 13 11 4 5 5 4 6
Region of residencea
Northeast 115 103 89 69 69 50 57 47 38 38
Midwest 16 14 11 14 26 10 10 14 7 7
South 95 96 82 77 86 53 52 53 38 50
West 112 114 112 99 119 58 58 60 62 65
Total 338 327 294 260 299 171 177 173 146 161
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 0 0 0 0 0 0 0 0 0
25–29 0 0 1 0 0 0 0 0 0 0
30–34 0 0 0 0 0 0 0 0 0 1
35–39 0 0 0 1 0 0 0 0 0 1
40–44 0 0 0 0 0 0 0 0 0 0
45–49 0 1 0 0 0 0 0 0 1 0
50–54 1 0 0 0 0 0 0 0 0 1
55–59 0 0 0 0 0 0 0 0 0 0
60–64 0 0 0 0 0 0 0 0 1 0
≥ 65 0 0 0 0 1 0 0 0 0 0
Region of residencea
Northeast 0 0 0 0 0 0 0 0 0 0
Midwest 0 0 1 1 0 0 0 0 0 0
South 0 0 0 0 0 0 0 0 0 1
West 1 1 0 0 1 0 0 0 1 2
Total 1 1 1 1 1 0 0 0 2 3
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 3 4 0 3 2 10 8 6 2 7
20–24 35 34 42 19 28 49 48 44 18 32
25–29 82 96 104 80 103 90 85 90 76 81
30–34 90 106 112 119 139 100 98 107 86 112
35–39 75 109 99 115 139 81 96 98 71 109
40–44 46 63 71 66 91 52 73 78 46 59
45–49 57 50 69 51 56 39 46 56 39 50
50–54 37 50 43 33 54 44 44 41 38 49
55–59 37 32 45 34 31 32 28 36 34 27
60–64 18 22 16 14 20 10 11 14 16 17
≥ 65 18 8 9 10 15 6 7 6 8 10
Region of residencea
Northeast 94 110 93 102 113 90 92 82 56 72
Midwest 93 117 106 91 122 93 111 100 64 110
South 195 214 272 247 316 236 228 282 230 277
West 115 132 138 104 128 93 113 110 85 93
Total 497 574 610 543 679 513 543 574 434 553
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 1 2 3 1 0 2
20–24 2 5 4 6 3 6 10 3 2 3
25–29 8 5 4 5 5 8 11 11 6 5
30–34 6 5 13 10 11 4 7 5 4 5
35–39 4 3 3 10 5 6 6 12 4 5
40–44 5 4 3 1 7 5 5 7 5 4
45–49 7 3 3 4 1 4 8 6 5 3
50–54 5 7 5 2 4 4 5 4 1 4
55–59 3 4 2 3 4 3 2 2 1 2
60–64 3 3 1 2 1 1 3 1 1 1
≥ 65 2 1 3 0 0 0 2 2 1 0
Region of residencea
Northeast 13 7 17 5 6 12 11 10 4 5
Midwest 11 7 8 9 6 6 9 11 7 5
South 12 16 12 22 20 18 28 25 14 18
West 8 11 5 8 9 7 13 8 5 6
Total 44 41 42 43 41 44 60 54 30 35
Total
Age at diagnosis (yr)
13–14 1 0 0 0 0 0 0 0 1 1
15–19 13 12 4 7 7 29 21 20 13 17
20–24 77 87 84 58 77 112 104 100 50 73
25–29 171 177 207 159 183 159 150 170 143 155
30–34 208 224 231 211 264 179 178 180 162 185
35–39 170 215 198 201 240 153 171 193 136 180
40–44 126 139 153 137 178 119 124 139 86 115
45–49 146 132 129 113 121 102 107 117 87 97
50–54 128 147 117 92 119 105 106 99 73 101
55–59 118 113 111 87 98 77 78 82 75 74
60–64 67 76 72 54 69 44 47 49 45 43
≥ 65 65 54 57 52 60 30 30 34 22 35
Region of residencea
Northeast 346 343 308 263 283 249 238 237 151 185
Midwest 184 199 184 162 209 170 180 180 129 183
South 479 527 560 499 617 485 473 538 417 496
West 282 307 310 245 307 205 226 228 197 211
Total 1,291 1,376 1,362 1,169 1,415 1,109 1,117 1,182 895 1,075

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States and 6 dependent areas
Male sex at birth Female sex at birth
2017 2018 2019 2020 (COVID-19 Pandemic) 2021 2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 0 0 0 0 0 0 0 1
20–24 0 0 2 1 0 1 0 2 0 1
25–29 6 1 0 0 3 2 3 1 5 5
30–34 3 3 2 4 1 2 2 2 4 4
35–39 0 0 3 1 0 2 4 6 4 2
40–44 1 0 3 0 2 2 1 2 1 0
45–49 0 1 1 0 2 2 2 1 2 2
50–54 3 2 1 2 0 3 2 2 0 3
55–59 0 0 0 0 0 0 1 0 1 1
60–64 1 0 0 0 0 1 1 0 0 0
≥ 65 1 0 0 0 0 1 0 1 0 0
Region of residencea
Northeast 1 0 0 0 0 1 0 0 0 0
Midwest 2 3 3 2 3 1 3 5 8 6
South 2 1 3 4 3 4 6 6 1 1
West 11 6 8 2 4 9 6 7 8 10
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 17 9 14 9 10 16 15 18 17 17
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 1 0 0 0 0 0 0 0 0
25–29 1 0 1 1 0 2 0 0 0 2
30–34 1 3 0 2 2 0 2 2 2 0
35–39 1 0 3 1 2 1 1 1 1 0
40–44 3 2 2 2 2 0 0 1 0 1
45–49 2 2 2 2 2 0 0 1 0 0
50–54 1 1 3 2 2 1 0 0 1 1
55–59 0 1 1 0 1 0 1 0 0 0
60–64 0 1 1 1 2 1 1 0 0 0
≥ 65 0 1 0 1 0 0 0 0 0 0
Region of residencea
Northeast 4 5 3 2 2 1 2 2 1 1
Midwest 0 1 3 2 4 0 0 0 0 1
South 2 4 2 1 1 1 2 1 2 2
West 4 1 6 8 6 3 2 3 2 2
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 10 11 14 13 14 5 5 6 5 6
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 5 4 3 2 2 12 9 7 8 5
20–24 19 22 20 18 25 35 23 32 18 24
25–29 34 45 50 33 33 36 30 45 37 36
30–34 49 43 58 42 50 39 42 42 36 38
35–39 44 53 42 33 48 39 36 42 31 37
40–44 30 35 39 28 43 42 29 39 21 33
45–49 42 41 31 30 30 41 32 37 29 29
50–54 42 49 37 29 33 40 40 34 25 29
55–59 55 51 40 37 43 33 38 33 30 31
60–64 32 36 42 23 34 25 24 27 18 19
≥ 65 33 36 32 28 31 19 16 20 10 19
Region of residencea
Northeast 120 118 107 85 94 95 76 97 52 68
Midwest 61 57 52 43 47 60 48 50 43 53
South 173 195 190 149 191 172 158 171 132 147
West 30 43 41 24 39 35 35 40 34 32
U.S. dependent areas 0 2 3 1 1 0 0 0 1 0
Total 385 415 391 301 373 362 318 358 261 300
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 1 0
15–19 5 3 1 2 1 5 2 6 3 3
20–24 23 24 17 14 21 20 25 19 11 12
25–29 43 32 46 39 40 21 21 23 19 25
30–34 64 67 47 37 61 35 28 22 30 27
35–39 46 50 52 42 49 26 29 35 26 26
40–44 44 39 39 45 38 18 16 13 15 18
45–49 41 38 24 28 32 18 20 19 11 13
50–54 48 43 30 26 28 14 15 19 10 14
55–59 27 27 26 16 21 10 10 11 10 12
60–64 16 17 15 15 15 8 9 7 9 6
≥ 65 15 10 17 14 13 4 5 5 5 6
Region of residencea
Northeast 115 103 89 69 69 50 57 47 38 38
Midwest 16 14 11 14 26 10 10 14 7 7
South 95 96 82 77 86 53 52 53 38 50
West 112 114 112 99 119 58 58 60 62 65
U.S. dependent areas 35 23 19 19 19 9 3 5 3 2
Total 372 350 313 278 318 179 179 178 149 162
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 0 0 0 0 0 0 0 0 0
25–29 0 0 1 0 0 0 0 0 0 0
30–34 0 0 0 0 0 0 0 0 0 1
35–39 0 0 0 1 0 0 0 0 0 1
40–44 0 0 0 0 0 0 0 0 0 0
45–49 0 1 0 0 0 0 0 0 1 0
50–54 1 0 0 0 0 0 0 0 0 1
55–59 0 0 0 0 0 0 0 0 0 0
60–64 0 0 0 0 0 0 0 0 1 0
≥ 65 0 0 0 0 1 0 0 0 0 0
Region of residencea
Northeast 0 0 0 0 0 0 0 0 0 0
Midwest 0 0 1 1 0 0 0 0 0 0
South 0 0 0 0 0 0 0 0 0 1
West 1 1 0 0 1 0 0 0 1 2
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 1 2 1 1 1 0 0 0 2 3
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 3 4 0 3 2 10 8 6 2 7
20–24 35 34 42 19 28 49 48 44 18 32
25–29 82 96 104 80 103 90 85 90 76 81
30–34 90 106 112 119 139 100 98 107 86 112
35–39 75 109 99 115 139 81 96 98 71 109
40–44 46 63 71 66 91 52 73 78 46 59
45–49 57 50 69 52 57 39 46 56 39 50
50–54 37 50 43 33 54 44 44 41 38 49
55–59 37 32 45 34 31 32 28 36 34 27
60–64 18 22 16 14 20 10 11 14 16 17
≥ 65 18 8 9 10 15 6 7 6 8 10
Region of residencea
Northeast 94 110 93 102 113 90 92 82 56 72
Midwest 93 117 106 91 122 93 111 100 64 110
South 195 214 272 247 316 236 228 282 230 277
West 115 132 138 104 128 93 113 110 85 93
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 497 574 610 543 679 513 543 574 434 553
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 1 2 3 1 0 2
20–24 2 5 4 6 3 6 10 3 2 3
25–29 8 5 4 5 5 8 11 11 6 5
30–34 6 5 13 10 11 4 7 5 4 5
35–39 5 3 3 10 5 6 6 12 4 5
40–44 5 4 3 1 7 5 5 7 5 4
45–49 7 3 3 4 1 4 8 6 5 3
50–54 5 7 5 2 4 4 5 4 1 4
55–59 3 4 2 3 4 3 2 2 1 2
60–64 3 3 1 2 1 1 3 1 1 1
≥ 65 2 1 3 0 0 0 2 2 1 0
Region of residencea
Northeast 13 7 17 5 6 12 11 10 4 5
Midwest 11 7 8 9 6 6 9 11 7 5
South 12 16 12 22 20 18 28 25 14 18
West 8 11 5 8 9 7 13 8 5 6
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 44 41 42 43 41 44 60 54 30 35
Total
Age at diagnosis (yr)
13–14 1 0 0 0 0 0 0 0 1 1
15–19 14 12 4 7 7 29 21 20 13 17
20–24 78 87 84 58 77 112 105 100 50 73
25–29 173 179 207 159 184 159 150 170 143 155
30–34 213 227 232 214 264 180 179 180 162 186
35–39 171 216 202 203 242 155 171 194 136 180
40–44 129 143 157 142 182 119 124 139 87 115
45–49 149 135 130 115 123 106 108 119 88 97
50–54 137 152 119 93 122 106 106 100 74 102
55–59 123 115 113 90 100 78 78 83 76 74
60–64 71 78 75 56 72 45 48 50 45 43
≥ 65 69 56 61 53 61 30 30 34 23 36
Region of residencea
Northeast 346 343 308 263 283 249 238 237 151 185
Midwest 184 199 184 162 209 170 180 180 129 183
South 479 527 560 499 617 485 473 538 417 496
West 282 307 310 245 307 205 226 228 197 211
U.S. dependent areas 35 25 22 20 20 9 3 5 4 2
Total 1,325 1,401 1,385 1,189 1,436 1,118 1,120 1,188 898 1,076

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, assigned sex at birth, race/ethnicity, and selected characteristics, 2017–2021—United States
Male sex at birth Female sex at birth
2017 2018 2019 2020
(COVID-19 Pandemic)
2021 2017 2018 2019 2020
(COVID-19 Pandemic)
2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 0 0 0 0 1 1 0 1
20–24 0 1 2 0 0 3 1 2 0 0
25–29 0 1 0 0 4 5 1 2 1 5
30–34 2 1 1 0 1 2 1 3 5 5
35–39 3 1 1 0 1 4 2 6 6 5
40–44 0 0 2 0 1 3 3 5 5 2
45–49 0 0 0 0 0 5 2 3 1 5
50–54 0 0 1 2 2 4 2 2 1 6
55–59 1 2 1 0 1 1 3 1 2 1
60–64 0 0 0 0 0 2 0 1 1 0
≥ 65 0 0 0 0 0 0 0 1 1 1
Region of residencea
Northeast 0 1 0 0 1 0 0 0 1 0
Midwest 0 2 2 0 2 3 1 9 4 10
South 3 3 6 1 3 5 7 5 7 7
West 4 3 1 1 5 20 7 11 11 12
Total 7 8 9 3 11 27 15 25 23 29
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 1 0 2 0 1 1 1
20–24 2 5 0 1 3 5 7 6 2 8
25–29 3 2 3 1 4 17 15 10 12 9
30–34 4 7 2 2 2 8 16 16 13 11
35–39 10 7 2 4 7 23 10 16 14 12
40–44 3 10 5 3 6 11 13 7 3 18
45–49 5 6 4 3 3 12 8 15 8 3
50–54 2 6 6 4 6 12 8 4 8 11
55–59 2 3 3 4 4 8 8 8 6 3
60–64 4 5 3 2 3 6 5 7 7 5
≥ 65 3 6 3 6 4 4 7 3 3 6
Region of residencea
Northeast 8 13 13 4 12 15 26 13 11 14
Midwest 6 2 1 3 3 19 5 11 10 11
South 11 22 11 13 18 30 27 29 21 32
West 13 18 7 9 7 45 38 38 35 28
Total 38 55 32 29 40 108 96 92 77 85
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 3 3 4 3 5
15–19 23 32 26 18 18 137 131 95 75 97
20–24 123 108 112 85 95 401 391 375 281 333
25–29 197 225 170 151 167 516 473 440 364 413
30–34 197 229 184 156 201 533 461 458 390 451
35–39 219 207 180 142 185 469 452 424 317 428
40–44 185 165 164 139 162 405 424 374 278 366
45–49 187 169 193 120 138 393 360 328 268 323
50–54 199 196 169 110 135 345 325 318 215 267
55–59 187 159 158 126 144 293 300 272 196 254
60–64 124 100 131 88 123 196 172 190 137 154
≥ 65 112 106 119 88 102 165 129 155 88 118
Region of residencea
Northeast 310 251 243 185 249 633 555 521 391 486
Midwest 191 202 187 135 141 499 478 475 362 409
South 1,186 1,164 1,108 852 1,012 2,485 2,317 2,187 1,666 2,085
West 65 79 68 52 68 237 271 250 193 228
Total 1,752 1,695 1,606 1,225 1,470 3,853 3,621 3,433 2,612 3,207
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 1 1 5 4 0 1
15–19 8 6 10 2 4 38 32 33 30 36
20–24 27 29 25 30 30 114 94 112 97 95
25–29 68 58 75 49 61 141 131 142 98 137
30–34 74 91 65 44 64 128 129 147 100 131
35–39 78 83 72 63 74 127 143 113 109 145
40–44 80 70 70 41 73 104 106 113 91 119
45–49 54 75 57 38 49 119 107 96 70 111
50–54 53 59 51 52 54 84 107 89 71 83
55–59 37 46 39 27 40 71 68 63 51 71
60–64 31 22 33 23 28 40 46 46 33 36
≥ 65 27 33 21 19 28 38 44 39 22 33
Region of residencea
Northeast 140 139 106 83 133 262 246 228 195 223
Midwest 31 33 33 18 27 63 55 70 45 60
South 272 314 293 221 257 454 469 455 353 468
West 93 86 83 65 89 226 240 245 178 246
Total 536 572 516 387 506 1,005 1,010 997 771 997
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 1 0 1 1 1 0
20–24 0 0 0 0 0 0 0 0 1 1
25–29 1 0 1 0 0 2 0 1 2 0
30–34 1 1 0 1 0 3 2 1 1 1
35–39 0 0 0 1 0 2 0 2 1 1
40–44 1 0 0 0 0 0 0 1 1 2
45–49 1 0 0 0 0 0 0 0 1 0
50–54 0 0 0 0 0 0 1 1 1 2
55–59 0 0 0 0 1 0 0 0 2 0
60–64 0 0 0 0 0 0 0 0 1 0
≥ 65 1 0 0 0 0 0 0 0 0 0
Region of residencea
Northeast 1 0 0 0 0 1 1 0 1 2
Midwest 0 0 0 0 0 0 0 4 0 0
South 1 1 0 0 1 2 0 1 4 1
West 2 0 1 2 1 4 3 2 8 4
Total 5 2 1 2 3 7 4 7 12 7
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 0 0 1
15–19 5 3 3 1 3 26 30 31 21 33
20–24 15 19 20 15 20 93 89 90 96 78
25–29 48 47 50 31 44 110 121 127 115 92
30–34 50 58 39 40 41 124 123 123 113 142
35–39 45 51 43 37 49 105 111 120 105 128
40–44 51 42 46 31 45 83 102 95 89 133
45–49 52 54 53 41 35 106 106 105 103 98
50–54 63 44 49 38 45 95 92 91 69 90
55–59 49 51 45 35 38 93 71 81 77 89
60–64 37 38 30 27 27 38 37 47 30 42
≥ 65 34 31 25 27 32 25 25 22 30 37
Region of residencea
Northeast 82 79 62 65 63 115 104 107 98 95
Midwest 49 54 60 52 51 147 160 177 147 189
South 240 240 214 167 213 485 486 481 421 503
West 76 65 67 40 53 151 160 167 181 174
Total 447 438 404 324 379 898 909 932 847 962
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 0 0
15–19 1 1 1 1 1 9 13 12 10 3
20–24 5 5 4 4 2 29 26 27 23 18
25–29 12 11 8 1 5 24 44 38 29 27
30–34 14 14 11 5 7 31 38 25 20 26
35–39 13 5 7 4 7 32 30 23 16 27
40–44 14 5 10 5 8 15 17 22 11 17
45–49 10 8 8 6 6 25 28 22 12 13
50–54 6 10 8 5 6 16 14 19 10 14
55–59 8 4 8 3 4 15 9 7 9 11
60–64 9 3 3 2 3 4 12 8 10 6
≥ 65 6 4 8 1 3 7 8 7 3 7
Region of residencea
Northeast 22 24 23 8 11 43 43 41 24 31
Midwest 12 9 14 5 12 31 34 33 30 21
South 56 34 34 20 26 106 127 108 86 96
West 8 3 5 3 2 27 33 29 13 21
Total 97 69 76 36 52 207 237 210 153 169
Total
Age at diagnosis (yr)
13–14 0 0 0 0 1 6 8 8 3 6
15–19 38 44 41 24 27 211 208 174 137 171
20–24 171 167 163 136 150 646 607 611 499 532
25–29 327 344 307 233 285 815 784 760 620 682
30–34 342 401 302 249 316 828 770 773 643 766
35–39 368 354 304 251 321 761 749 704 569 745
40–44 333 292 296 219 294 621 665 617 477 656
45–49 308 312 315 208 231 658 611 569 463 552
50–54 323 314 284 210 247 555 548 523 375 472
55–59 284 264 254 195 232 480 459 432 343 428
60–64 205 168 200 141 185 287 271 297 219 243
≥ 65 183 179 176 140 170 238 213 227 148 202
Region of residencea
Northeast 564 506 448 344 469 1,068 974 910 721 851
Midwest 289 301 297 214 237 761 733 778 598 700
South 1,768 1,778 1,666 1,275 1,529 3,567 3,433 3,266 2,556 3,192
West 261 253 232 173 224 710 751 742 619 713
Total 2,882 2,839 2,643 2,006 2,460 6,106 5,892 5,695 4,494 5,456

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified heterosexual contact include transgender and additional gender identity persons. Includes persons who have ever had heterosexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs). Excludes men who have ever had sexual contact with both men and women.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, assigned sex at birth, race/ethnicity and selected characteristics, 2017–2021—United States and 6 dependent areas
Male sex at birth Female sex at birth
2017 2018 2019 2020
(COVID-19 Pandemic)
2021 2017 2018 2019 2020
(COVID-19 Pandemic)
2021
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 0 0 0 0 1 1 0 1
20–24 0 1 2 0 0 3 1 2 0 0
25–29 0 1 0 0 4 5 1 2 1 5
30–34 2 1 1 0 1 2 1 3 5 5
35–39 3 1 1 0 1 4 2 6 6 5
40–44 0 0 2 0 1 3 3 5 5 2
45–49 0 0 0 0 0 5 2 3 1 5
50–54 0 0 1 2 2 4 2 2 1 6
55–59 1 2 1 0 1 1 3 1 2 1
60–64 0 0 0 0 0 2 0 1 1 0
≥ 65 0 0 0 0 0 0 0 1 1 1
Region of residencea
Northeast 0 1 0 0 1 0 0 0 1 0
Midwest 0 2 2 0 2 3 1 9 4 10
South 3 3 6 1 3 5 7 5 7 7
West 4 3 1 1 5 20 7 11 11 12
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 7 8 9 3 11 27 15 25 23 29
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 1 0 2 0 1 1 1
20–24 2 5 0 1 3 5 7 6 2 8
25–29 3 2 3 1 4 17 15 10 12 9
30–34 4 7 2 2 2 8 16 16 13 11
35–39 10 7 2 4 7 23 10 16 14 12
40–44 3 10 5 3 6 11 13 7 3 18
45–49 5 6 4 3 3 12 8 15 8 3
50–54 2 6 6 4 6 12 8 4 8 11
55–59 2 3 3 4 4 8 8 8 6 3
60–64 4 5 3 2 3 6 5 7 7 5
≥ 65 3 6 3 6 4 4 7 3 3 6
Region of residencea
Northeast 8 13 13 4 12 15 26 13 11 14
Midwest 6 2 1 3 3 19 5 11 10 11
South 11 22 11 13 18 30 27 29 21 32
West 13 18 7 9 7 45 38 38 35 28
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 38 55 32 29 40 108 96 92 77 85
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 3 3 4 3 5
15–19 23 32 26 18 18 137 131 95 75 97
20–24 123 108 112 85 95 401 391 375 281 333
25–29 197 226 170 151 167 516 473 440 364 413
30–34 197 229 184 157 201 534 461 458 390 451
35–39 219 207 180 142 185 469 452 425 317 428
40–44 185 165 164 139 162 405 424 374 278 366
45–49 187 170 193 120 138 393 360 328 268 323
50–54 199 196 169 110 135 345 325 319 215 268
55–59 187 161 158 126 144 294 300 272 197 254
60–64 124 100 131 88 124 196 172 191 137 154
≥ 65 112 107 119 89 102 165 130 155 88 118
Region of residencea
Northeast 310 251 243 185 249 633 555 521 391 486
Midwest 191 202 187 135 141 499 478 475 362 409
South 1,186 1,164 1,108 852 1,012 2,485 2,317 2,187 1,666 2,085
West 65 79 68 52 68 237 271 250 193 228
U.S. dependent areas 0 5 0 2 0 3 1 3 2 1
Total 1,753 1,700 1,607 1,226 1,470 3,856 3,622 3,436 2,613 3,208
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 1 1 5 4 0 1
15–19 9 7 10 2 7 40 34 33 30 38
20–24 35 31 28 32 31 119 102 116 102 104
25–29 72 66 77 52 63 152 138 147 102 140
30–34 82 99 71 45 69 134 134 156 101 135
35–39 88 88 76 67 78 137 147 117 112 158
40–44 89 72 77 45 80 111 114 125 96 132
45–49 59 79 68 41 59 130 120 105 74 118
50–54 59 72 55 57 65 94 118 94 75 93
55–59 45 50 49 35 44 82 76 75 58 74
60–64 41 27 40 28 33 44 50 51 36 43
≥ 65 36 42 32 22 40 42 50 48 26 42
Region of residencea
Northeast 140 139 106 83 133 262 246 228 195 223
Midwest 31 33 33 18 27 63 55 70 45 60
South 272 314 293 221 257 454 469 455 353 468
West 93 86 83 65 89 226 240 245 178 246
U.S. dependent areas 79 61 64 38 63 80 77 74 41 80
Total 615 633 580 426 569 1,085 1,088 1,071 812 1,077
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 1 0 1 1 1 0
20–24 1 0 0 0 0 0 0 1 1 1
25–29 1 0 1 0 0 2 0 1 2 0
30–34 1 1 0 1 0 3 2 1 1 1
35–39 0 0 0 1 0 2 0 2 1 1
40–44 1 0 0 0 0 0 0 1 1 2
45–49 1 0 0 0 0 0 0 0 1 0
50–54 0 0 0 0 0 0 1 1 1 2
55–59 0 0 0 0 1 0 0 0 2 0
60–64 0 0 0 0 0 0 0 0 1 0
≥ 65 1 0 0 0 0 0 0 0 0 0
Region of residencea
Northeast 1 0 0 0 0 1 1 0 1 2
Midwest 0 0 0 0 0 0 0 4 0 0
South 1 1 0 0 1 2 0 1 4 1
West 2 0 1 2 1 4 3 2 8 4
U.S. dependent areas 1 0 0 0 0 0 0 1 0 0
Total 6 2 1 2 3 7 4 8 12 7
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 0 0 1
15–19 5 3 3 1 3 26 30 31 21 33
20–24 15 19 20 15 20 93 89 90 96 78
25–29 48 47 50 31 44 110 121 127 115 92
30–34 50 58 39 40 41 124 123 123 113 142
35–39 45 51 43 37 49 105 111 120 105 128
40–44 51 42 46 31 45 83 102 95 89 133
45–49 52 55 54 41 35 106 106 105 103 98
50–54 63 44 49 38 45 96 92 91 69 90
55–59 49 51 45 35 38 93 71 81 77 89
60–64 37 38 30 27 27 38 37 47 30 42
≥ 65 34 31 25 27 32 25 25 22 30 37
Region of residencea
Northeast 82 79 62 65 63 115 104 107 98 95
Midwest 49 54 60 52 51 147 160 177 147 189
South 240 240 214 167 213 485 486 481 421 503
West 76 65 67 40 53 151 160 167 181 174
U.S. dependent areas 0 0 1 0 0 1 0 0 0 0
Total 447 438 405 324 379 899 909 932 847 962
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 0 0
15–19 1 1 1 1 1 9 13 12 10 3
20–24 5 5 4 4 2 29 26 27 23 18
25–29 12 11 8 1 5 24 44 38 29 27
30–34 14 14 11 5 7 31 38 25 20 26
35–39 13 6 7 4 7 32 30 23 16 27
40–44 14 5 10 5 8 15 17 22 11 17
45–49 10 8 8 6 6 25 28 22 12 13
50–54 6 10 8 5 6 16 14 19 10 14
55–59 8 4 8 3 4 15 9 7 9 11
60–64 9 3 3 2 3 4 12 8 10 6
≥ 65 6 4 8 1 3 7 8 7 3 7
Region of residencea
Northeast 22 24 23 8 11 43 43 41 24 31
Midwest 12 9 14 5 12 31 34 33 30 21
South 56 34 34 20 26 106 127 108 86 96
West 8 3 5 3 2 27 33 29 13 21
U.S. dependent areas 0 1 0 0 0 1 0 0 0 0
Total 97 70 76 36 52 208 237 210 153 169
Total
Age at diagnosis (yr)
13–14 0 0 0 0 1 6 8 8 3 6
15–19 39 45 41 24 30 214 210 174 137 173
20–24 180 169 166 138 151 651 615 616 504 541
25–29 331 353 309 236 288 826 791 765 624 685
30–34 351 409 308 251 321 834 775 782 644 770
35–39 378 360 308 255 326 771 753 709 572 758
40–44 342 295 303 222 301 628 673 629 482 669
45–49 313 317 327 211 241 670 625 578 467 559
50–54 329 328 289 215 258 566 559 529 379 482
55–59 292 270 264 203 236 492 467 444 350 431
60–64 215 173 207 147 190 291 276 303 222 250
≥ 65 192 188 187 144 181 242 220 236 152 211
Region of residencea
Northeast 564 506 448 344 469 1,068 974 910 721 851
Midwest 289 301 297 214 237 761 733 778 598 700
South 1,768 1,778 1,666 1,275 1,529 3,567 3,433 3,266 2,556 3,192
West 261 253 232 173 224 710 751 742 619 713
U.S. dependent areas 81 68 66 40 63 84 78 78 42 80
Total 2,962 2,906 2,709 2,046 2,523 6,190 5,970 5,773 4,536 5,536

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified heterosexual contact include transgender and additional gender identity persons. Includes persons who have ever had heterosexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs). Excludes men who have ever had sexual contact with both men and women.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 8a. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, assigned sex at birth, and selected characteristics, 2021—United States
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Sex at birth
Male 8 0.2 260 3.9 990 22.6 2,788 42.1 2,052 47.1 6,098 23.0
Female 7 0.2 63 1.0 139 3.3 349 5.5 271 6.5 829 3.3
Race/Ethnicity
American Indian/Alaska Native 0 0.0 2 1.8 10 14.1 14 12.8 7 9.8 33 7.6
Asian 0 0.0 2 0.3 21 4.6 43 6.0 51 10.1 117 4.2
Black/African American 8 0.7 194 11.0 631 54.1 1,720 94.6 1,144 95.0 3,697 51.5
Hispanic/Latinob 6 0.3 81 2.5 287 13.8 783 25.8 697 36.1 1,854 14.7
Native Hawaiian/Other Pacific Islander 0 0.0 2 7.6 4 23.5 3 11.8 2 11.6 11 10.6
White 1 0.0 28 0.4 128 2.9 468 6.8 346 7.6 971 3.6
Multiracial 0 0.0 14 2.7 48 15.6 106 24.1 76 28.0 244 12.8
Transmission categoryc
Male sex at birthd
Male-to-male sexual contacte 5 246 947 2,599 1,874 5,671
Injection drug usef 0 1 5 36 41 84
Male-to-male sexual contacte and injection drug usef 1 3 16 67 70 156
Heterosexual contactg 1 6 21 84 66 178
Perinatalh 1 3 1 2 1 8
Otheri 0 0 0 0 0 0
Subtotal 8 0.2 260 3.9 990 22.6 2,788 42.1 2,052 47.1 6,098 23.0
Female sex at birthd
Injection drug usef 1 4 13 36 37 91
Heterosexual contactg 6 51 121 304 229 710
Perinatalh 0 8 5 10 5 28
Otheri 0 0 0 0 0 0
Subtotal 7 0.2 63 1.0 139 3.3 349 5.5 271 6.5 829 3.3
Region of residencej
Northeast 2 0.1 54 2.6 120 8.1 378 17.3 322 23.0 876 10.2
Midwest 5 0.3 45 1.6 156 8.7 475 17.1 304 17.1 985 9.0
South 5 0.1 163 3.2 675 20.6 1,793 36.0 1,275 38.9 3,911 19.5
West 3 0.1 61 2.0 178 8.9 491 16.2 422 20.2 1,155 9.3
Total 15 0.2 323 2.5 1,129 13.2 3,137 24.2 2,323 27.2 6,927 13.3

Note: Numbers less than 12 should be interpreted with caution.

a Hispanic/Latino persons can be of any race.
b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
c Data include transgender and additional gender identity persons.
d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at time of diagnosis of HIV infection.

Table 8b. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis, assigned sex at birth, and selected characteristics, 2021—United States and 6 dependent areas
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. No. No. No. No. No.
Sex at birth
Male 8 260 996 2,814 2,069 6,147
Female 7 64 140 353 276 840
Race/Ethnicity
American Indian/Alaska Native 0 2 10 14 7 33
Asian 0 2 21 43 51 117
Black/African American 8 194 631 1,721 1,144 3,698
Hispanic/Latinoa 6 82 294 812 719 1,913
Native Hawaiian/Other Pacific Islander 0 2 4 3 2 11
White 1 28 128 468 346 971
Multiracial 0 14 48 106 76 244
Transmission categoryb
Male sex at birthc
Male-to-male sexual contactd 5 246 949 2,625 1,890 5,715
Injection drug usee 0 1 5 36 41 84
Male-to-male sexual contactd and injection drug usee 1 3 17 67 70 157
Heterosexual contactf 1 6 24 84 67 182
Perinatalg 1 3 1 2 1 8
Otherh 0 0 0 0 0 0
Subtotal 8 260 996 2,814 2,069 6,147
Female sex at birthc
Injection drug usee 1 4 13 36 37 91
Heterosexual contactf 6 52 122 308 234 721
Perinatalg 0 8 5 10 5 28
Otherh 0 0 0 0 0 0
Subtotal 7 64 140 353 276 840
Region of residencei
Northeast 2 54 120 378 322 876
Midwest 5 45 156 475 304 985
South 5 163 675 1,793 1,275 3,911
West 3 61 178 491 422 1,155
U.S. dependent areas 0 1 7 30 22 60
Total 15 324 1,136 3,167 2,345 6,987

Note: Numbers less than 12 should be interpreted with caution.

a Hispanic/Latino persons can be of any race.
b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
c Data include transgender and additional gender identity persons.
d Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
e Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
f Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Data are based on residence at time of diagnosis of HIV infection.

Table 9a. Diagnoses of HIV infection among children aged < 13 years, by year of diagnosis and race/ethnicity, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
American Indian/Alaska Native 0 0.0 0 0.0 1 0.2 1 0.2 0 0.0
Asian 8 0.3 6 0.2 6 0.2 2 0.1 2 0.1
Black/African American 56 0.8 49 0.7 31 0.4 35 0.5 33 0.5
Hispanic/Latinob 15 0.1 10 0.1 7 0.1 9 0.1 11 0.1
Native Hawaiian/other Pacific Islander 1 0.9 0 0.0 0 0.0 1 0.9 0 0.0
White 15 0.1 15 0.1 7 0.0 12 0.0 5 0.0
Multiracial 10 0.4 6 0.2 5 0.2 0 0.0 2 0.1
Total 105 0.2 86 0.2 57 0.1 60 0.1 53 0.1

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population.
b Hispanic/Latino persons can be of any race.

Table 9b. Diagnoses of HIV infection among children aged < 13 years, by year of diagnosis and race/ethnicity, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
American Indian/Alaska Native 0 0 1 1 0
Asian 8 6 6 2 2
Black/African American 56 49 31 35 33
Hispanic/Latinoa 15 10 7 9 11
Native Hawaiian/other Pacific Islander 1 0 0 1 0
White 15 15 7 12 5
Multiracial 10 6 5 0 2
Total 105 86 57 60 53

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a Hispanic/Latino persons can be of any race.

Table 10a. Diagnoses of HIV infection among Hispanic/Latino persons aged ≥ 13 years, by place of birth and transmission category, 2021—United States and 6 dependent areas
Caribbeana
United States South Americab Central Americac Mexico Puerto Rico Cuba Other Total
No. % No. % No. % No. % No. % No. % No. % No.d %
Transmission categorye
Male sex at birthf
Male-to-male sexual contactg 2,472 85.4 646 92.2 442 90.1 827 86.8 325 77.7 302 90.6 117.0 72.9 8,000 86.8
Injection drug useh 105 3.6 8 1.1 8 1.6 24 2.5 26 6.1 2 0.5 5.0 3.3 318 3.4
Male-to-male sexual contactg
and injection drug useh
159 5.5 7 1 6 1.1 25 2.6 7 1.6 2 0.5 3.0 2.0 327 3.5
Heterosexual contacti 157 5.4 39 5.6 33 6.7 77 8.0 61 14.5 28 8.4 35.0 21.7 569 6.2
Perinatalj 0 0.0 1 0.2 2 0.4 0 0.0 0 0.0 0 0.0 0.0 0.0 3 0.0
Otherk 1 0.0 0 0.0 0 0 1 0.1 0 0.0 0 0.0 0.0 0.1 4 0.0
Subtotal 2,894 100 701 100 491 100 953 100 418 100 333 100 161 100 9,222 100
Female sex at birthf
Injection drug useh 71 18.3 3 4 5 4.3 6 9.1 6 6.0 1 1.1 5.0 6.8 162 13.0
Heterosexual contacti 315 81.5 69 94.7 99 92.9 62 90.3 93 94.0 46 98.5 64.0 93.0 1,077 86.5
Perinatalj 1 0.2 1 1.4 3 2.7 0 0.6 0 0.0 0 0.4 0.0 0.1 6 0.5
Otherk 0 0.0 0 0 0 0.1 0 0.0 0 0.0 0 0.0 0.0 0.0 0 0.0
Subtotal 387 100 73 100 107 100 69 100 99 100 47 100 69 100 1,245 100
Total 3,281 100 774 100 598 100 1,022 100 517 100 380 100 230 100 10,467 100

Note. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S.).
b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
d Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Data include transgender and additional gender identity persons.
g Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
j Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
k Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

TTable 10b. Diagnoses of HIV infection among transgender and additional gender identity Hispanic/Latino persons ≥ 13 years, by place of birth and exposure category, 2021—United States and 6 dependent areas
Caribbeana
United States South Americab Central Americac Mexico Puerto Rico Cuba Other Total
No. % No. % No. % No. % No. % No. % No. % No.d %
Exposure categorye
Transgender womanf
Sexual contactg 74 88.1 8 100 23 100 33 97.1 6 85.7 7 100 5 100 237 91.9
Injection drug useh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.4
Sexual contactg
and injection drug useh
8 9.5 0 0.0 0 0.0 0 0.0 1 14.3 0 0.0 0 0.0 13 5.0
Otheri 2 2.4 0 0.0 0 0.0 1 2.9 0 0.0 0 0.0 0 0.0 7 2.7
Subtotal 84 100 8 100 23 100 34 100 7 100 7 100 5 100 258 100
Transgender manf
Sexual contactg 9 90.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 12 85.7
Injection drug useh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactg
and injection drug useh
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Otheri 1 10.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 14.3
Subtotal 10 100 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 14 100
Additional gender identityj
Sexual contactg 7 77.8 0 0.0 1 100 0 0.0 0 0.0 0 0.0 1 100 11 78.6
Injection drug useh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactg
and injection drug useh
1 11.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 14.3
Otheri 1 11.1 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 7.1
Subtotal 9 100 0 0.0 1 100 0 0.0 0 0.0 0 0.0 1 100 14 100
Total 103 100 8 100 24 100 34 100 7 100 7 100 6 100 286 100

Note. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

a Countries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S.).
b Countries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
c Countries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
d Total includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
e Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
f “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
g For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
h Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
i Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 11a. Deaths (any cause) of persons with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 12,240 12,102 12,309 14,210 14,663
Female 3,989 3,986 3,841 4,630 4,743
Transgender woman/girlb 108 118 145 207 215
Transgender man/boyb 5 5 5 10 2
Additional gender identityc 3 1 2 0 1
Age at death (yr)
< 13 2 0.0 1 0.0 2 0.0 5 0.0 1 0.0
13–14 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0
15–19 7 0.0 9 0.0 11 0.1 13 0.1 4 0.0
20–24 145 0.7 121 0.6 123 0.6 140 0.7 105 0.5
25–29 445 1.9 420 1.8 436 1.9 461 2.0 459 2.0
30–34 602 2.7 614 2.8 664 3.0 797 3.5 901 3.9
35–39 863 4.1 814 3.8 858 3.9 940 4.2 1,070 4.8
40–44 970 5.0 960 4.9 937 4.7 1,134 5.5 1,177 5.6
45–49 1,742 8.3 1,603 7.7 1,402 6.9 1,511 7.4 1,522 7.7
50–54 2,727 12.8 2,580 12.4 2,246 11.0 2,347 11.3 2,261 10.8
55–59 2,967 13.5 2,930 13.4 2,921 13.4 3,299 15.0 3,370 15.6
60–64 2,487 12.5 2,525 12.4 2,669 13.0 3,177 15.1 3,269 15.4
≥ 65 3,388 6.7 3,635 6.9 4,032 7.5 5,233 9.6 5,485 9.8
Race/ethnicity
American Indian/Alaska Native 47 2.0 49 2.0 57 2.4 82 3.4 80 3.3
Asiand 88 0.5 83 0.4 100 0.5 103 0.5 125 0.6
Black/African American 7,194 17.7 6,982 17.1 7,009 17.0 8,330 20.0 8,402 20.1
Hispanic/Latinoe 2,693 4.6 2,838 4.8 2,771 4.6 3,452 5.6 3,499 5.6
Native Hawaiian/other Pacific Islander 9 1.5 13 2.2 14 2.3 11 1.8 14 2.2
White 5,235 2.6 5,150 2.6 5,256 2.7 5,756 2.9 6,025 3.1
Multiracial 1,077 15.4 1,097 15.3 1,091 14.8 1,322 17.3 1,478 19.0
Transmission categoryf
Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contacth 7,010 6,888 7,184 8,237 8,672
Injection drug usei 2,154 2,169 2,087 2,427 2,335
Male-to-male sexual contacth
and injection drug usei
1,383 1,453 1,395 1,665 1,687
Heterosexual contactj 1,694 1,600 1,688 1,961 2,071
Perinatalk 41 51 41 57 54
Otherl 67 58 59 67 60
Subtotal 12,350 9.3 12,220 9.1 12,454 9.2 14,415 10.5 14,879 10.8
Female sex at birth (≥ 13 yrs at death)g
Injection drug usei 1,373 1,335 1,316 1,494 1,466
Heterosexual contactj 2,548 2,594 2,470 3,060 3,191
Perinatalk 43 37 37 45 52
Otherl 29 26 24 38 36
Subtotal 3,993 2.9 3,991 2.8 3,846 2.7 4,637 3.3 4,744 3.3
Child (< 13 yrs at death)
Perinatal 2 1 1 4 1
Otherl 0 0 1 1 0
Subtotal 2 0.0 1 0.0 2 0.0 5 0.0 1 0.0
Region of residencem
Northeast 3,693 6.6 3,523 6.3 3,653 6.5 4,524 7.9 4,324 7.6
Midwest 1,915 2.8 2,003 2.9 1,961 2.9 2,316 3.4 2,284 3.3
South 7,997 6.5 7,880 6.3 7,917 6.3 9,078 7.2 9,540 7.5
West 2,740 3.5 2,806 3.6 2,771 3.5 3,139 4.0 3,476 4.4
Totaln 16,345 5.0 16,212 5.0 16,302 5.0 19,057 5.7 19,624 5.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
n Includes persons whose race/ethnicity is unknown.

Table 11b. Deaths (any cause) of persons with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 12,541 12,392 12,585 14,484 14,942
Female 4,097 4,062 3,920 4,716 4,825
Transgender woman/girlb 110 119 147 208 216
Transgender man/boyb 5 5 5 10 2
Additional gender identityc 3 1 2 0 1
Age at death (yr)
< 13 2 0.0 1 0.0 2 0.0 5 0.0 1 0.0
13–14 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0
15–19 7 0.0 9 0.0 11 0.1 13 0.1 4 0.0
20–24 147 0.7 125 0.6 125 0.6 142 0.7 106 0.5
25–29 451 1.9 428 1.8 442 1.9 463 2.0 467 2.1
30–34 617 2.8 626 2.8 676 3.0 803 3.5 906 3.9
35–39 878 4.1 833 3.8 875 4.0 963 4.3 1,084 4.8
40–44 1,005 5.1 989 5.0 976 4.8 1,165 5.6 1,206 5.7
45–49 1,794 8.5 1,641 7.8 1,438 7.0 1,546 7.5 1,552 7.8
50–54 2,804 13.0 2,631 12.5 2,319 11.2 2,393 11.4 2,302 10.9
55–59 3,049 13.7 3,000 13.5 2,973 13.4 3,374 15.1 3,429 15.7
60–64 2,529 12.5 2,574 12.5 2,722 13.1 3,227 15.2 3,325 15.5
≥ 65 3,473 6.7 3,722 7.0 4,099 7.5 5,324 9.6 5,604 9.9
Race/ethnicity
American Indian/Alaska Native 47 49 57 82 80
Asiand 88 83 100 104 125
Black/African American 7,199 6,982 7,010 8,333 8,405
Hispanic/Latinoe 3,098 3,200 3,120 3,807 3,858
Native Hawaiian/other Pacific Islander 9 16 16 11 14
White 5,236 5,151 5,258 5,758 6,025
Multiracial 1,077 1,098 1,094 1,322 1,478
Transmission categoryf
Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contacth 7,081 6,967 7,257 8,319 8,730
Injection drug usei 2,286 2,290 2,209 2,534 2,451
Male-to-male sexual contacth
and injection drug usei
1,408 1,475 1,420 1,695 1,714
Heterosexual contactj 1,768 1,663 1,744 2,015 2,149
Perinatalk 42 57 43 60 55
Otherl 67 59 59 67 60
Subtotal 12,653 9.4 12,511 9.2 12,732 9.3 14,690 10.6 15,159 10.9
Female sex at birth (≥ 13 yrs at death)g
Injection drug usei 1,409 1,368 1,345 1,521 1,486
Heterosexual contactj 2,620 2,635 2,517 3,119 3,253
Perinatalk 44 39 38 45 52
Otherl 29 26 25 38 36
Subtotal 4,101 2.9 4,067 2.9 3,925 2.8 4,723 3.3 4,826 3.4
Child (< 13 yrs at death)
Perinatal 2 1 1 4 1
Otherl 0 0 1 1 0
Subtotal 2 0.0 1 0.0 2 0.0 5 0.0 1 0.0
Region of residencem
Northeast 3,693 6.6 3,523 6.3 3,653 6.5 4,524 7.9 4,324 7.6
Midwest 1,915 2.8 2,003 2.9 1,961 2.9 2,316 3.4 2,284 3.3
South 7,997 6.5 7,880 6.3 7,917 6.3 9,078 7.2 9,540 7.5
West 2,740 3.5 2,806 3.6 2,771 3.5 3,139 4.0 3,476 4.4
U.S. dependent areas 411 11.0 367 10.2 357 9.9 361 9.8 362 9.9
Totaln 16,756 5.1 16,579 5.0 16,659 5.0 19,418 5.8 19,986 6.0

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.

b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
n Includes persons whose race/ethnicity is unknown.

Table 12a. Deaths (any cause) of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2021—United States
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated
Gender
Male 53 100 5,599 2,720 14 5,076 1,101 14,663
Female 22 23 2,703 720 0 923 351 4,743
Transgender woman/girle 5 2 99 58 0 26 25 215
Transgender man/boye 0 0 1 1 0 0 0 2
Additional gender identityf 0 0 0 0 0 0 1 1
Age at death (yr)
< 13 0 0.0 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0 0 0.0 1 0.0
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 0 0.0 0 0.0 3 0.1 1 0.0 0 0.0 0 0.0 0 0.0 4 0.0
20–24 0 0.0 0 0.0 50 1.7 29 0.6 0 0.0 18 0.2 8 1.1 105 0.5
25–29 2 1.1 4 0.3 239 7.3 95 2.0 0 0.0 85 0.7 34 5.5 459 2.0
30–34 10 5.3 8 0.5 423 12.9 202 4.3 0 0.0 193 1.5 65 13.1 901 3.9
35–39 8 4.9 9 0.5 491 17.1 233 5.1 1 1.9 259 2.1 69 17.3 1,070 4.8
40–44 12 8.0 8 0.5 499 18.4 255 5.8 2 4.4 307 2.6 94 27.4 1,177 5.6
45–49 11 7.9 16 1.1 647 25.9 304 7.7 1 2.6 436 3.8 107 38.1 1,522 7.7
50–54 4 2.8 19 1.5 931 36.2 442 12.4 4 10.9 680 5.2 181 70.4 2,261 10.8
55–59 9 5.9 19 1.6 1,351 51.6 591 19.2 3 8.4 1,114 7.8 283 119.9 3,370 15.6
60–64 10 6.8 14 1.3 1,412 57.7 511 20.8 2 6.3 1,078 7.2 242 110.9 3,269 15.4
≥ 65 14 4.3 28 1.0 2,356 44.6 835 16.5 1 1.5 1,855 4.4 395 83.1 5,485 9.8
Transmission categoryg
Male sex at birth (≥ 13 yrs at death)h
Male-to-male sexual contacti 34 82 2,746 1,561 12 3,603 634 8,672
Injection drug usej 8 4 1,085 544 0 521 173 2,335
Male-to-male sexual contacti
and injection drug usej
11 3 483 354 1 653 184 1,687
Heterosexual contactk 5 12 1,344 291 1 295 123 2,071
Perinatall 0 0 28 15 0 5 5 54
Otherm 0 1 13 13 0 25 8 60
Subtotal 58 5.8 102 1.3 5,698 34.5 2,778 11.2 14 5.4 5,102 6.0 1,127 44.1 14,879 10.8
Female sex at birth (≥ 13 yrs at death)h
Injection drug usej 10 5 687 256 0 383 125 1,466
Heterosexual contactk 13 18 1,976 447 0 521 217 3,191
  Perinatall 0 0 31 12 0 6 2 52
Otherm 0 0 10 6 0 12 7 36
Subtotal 22 2.1 23 0.3 2,704 14.8 720 3.0 0 0.0 923 1.1 351 13.1 4,744 3.3
Child (< 13 yrs at death)
Perinatal 0 0 0 1 0 0 0 1
Otherm 0 0 0 0 0 0 0 0
Subtotal 0 0.0 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0 0 0.0 1 0.0
Region of residencen
Northeast 1 0.8 23 0.6 1,653 25.4 1,225 14.0 0 0.0 993 2.7 429 40.5 4,324 7.6
Midwest 6 1.4 12 0.5 944 12.9 188 3.2 2 4.9 930 1.8 202 13.5 2,284 3.3
South 9 1.1 28 0.6 5,208 21.3 1,155 4.8 1 1.0 2,554 3.6 585 22.4 9,540 7.5
West 64 6.0 62 0.7 597 16.4 931 3.9 11 2.4 1,548 4.0 262 10.0 3,476 4.4
Total 80 3.3 125 0.6 8,402 20.1 3,499 5.6 14 2.2 6,025 3.1 1,478 19.0 19,624 5.9

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for the year 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12 should be interpreted with caution.

a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
h Data include transgender and additional gender identity persons.
i Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
j Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
k Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
l Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
m Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
n Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 12b. Deaths (any cause) of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2021—United States and 6 dependent areas
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. No. No. No. No. No. No. No.
Gender
Male 53 100 5,601 2,997 14 5,076 1,101 14,942
Female 22 23 2,704 801 0 923 351 4,825
Transgender woman/girld 5 2 99 59 0 26 25 216
Transgender man/boyd 0 0 1 1 0 0 0 2
Additional gender identitye 0 0 0 0 0 0 1 1
Age at death (yr)
< 13 0 0 0 1 0 0 0 1
13–14 0 0 0 0 0 0 0 0
15–19 0 0 3 1 0 0 0 4
20–24 0 0 50 30 0 18 8 106
25–29 2 4 240 102 0 85 34 467
30–34 10 8 423 207 0 193 65 906
35–39 8 9 491 247 1 259 69 1,084
40–44 12 8 499 284 2 307 94 1,206
45–49 11 16 647 334 1 436 107 1,552
50–54 4 19 931 483 4 680 181 2,302
55–59 9 19 1,351 650 3 1,114 283 3,429
60–64 10 14 1,412 567 2 1,078 242 3,325
≥ 65 14 28 2,358 952 1 1,855 395 5,604
Transmission categoryf
Male sex at birth (≥ 13 yrs at death)g
Male-to-male sexual contacth 34 82 2,748 1,617 12 3,603 634 8,730
Injection drug usei 8 4 1,085 660 0 521 173 2,451
Male-to-male sexual contacth
and injection drug usei
11 3 483 380 1 653 184 1,714
Heterosexual contactj 5 12 1,344 370 1 295 123 2,149
Perinatalk 0 0 28 16 0 5 5 55
Otherl 0 1 13 13 0 25 8 60
Subtotal 58 102 5,700 3,056 14 5,102 1,127 15,159
Female sex at birth (≥ 13 yrs at death)g
Injection drug usei 10 5 687 276 0 383 125 1,486
Heterosexual contactj 13 18 1,977 507 0 521 217 3,253
Perinatalk 0 0 31 12 0 6 2 52
Otherl 0 0 10 6 0 12 7 36
Subtotal 22 23 2,705 801 0 923 351 4,826
Child (< 13 yrs at death)
Perinatal 0 0 0 1 0 0 0 1
Otherl 0 0 0 0 0 0 0 0
Subtotal 0 0 0 1 0 0 0 1
Region of residencem
Northeast 1 23 1,653 1,225 0 993 429 4,324
Midwest 6 12 944 188 2 930 202 2,284
South 9 28 5,208 1,155 1 2,554 585 9,540
West 64 62 597 931 11 1,548 262 3,476
U.S. dependent areas 0 0 3 359 0 0 0 362
Total 80 125 8,405 3,858 14 6,025 1,478 19,986

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for the year 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12 should be interpreted with caution.

a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
e Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 13a. Deaths (any cause) of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, assigned sex at birth, and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0
15–19 5 0.0 5 0.0 9 0.1 9 0.1 4 0.0
20–24 113 1.0 95 0.9 95 0.9 110 1.0 81 0.7
25–29 347 2.9 346 2.9 370 3.1 361 3.1 366 3.2
30–34 447 4.0 464 4.1 510 4.5 603 5.2 746 6.4
35–39 624 5.9 577 5.4 618 5.7 696 6.2 837 7.4
40–44 659 6.8 633 6.5 643 6.5 806 7.8 842 7.9
45–49 1,226 11.8 1,130 11.0 983 9.7 1,046 10.3 1,067 10.8
50–54 2,035 19.4 1,901 18.5 1,668 16.5 1,749 16.9 1,628 15.6
55–59 2,246 21.0 2,255 21.2 2,277 21.4 2,544 23.4 2,526 23.8
60–64 1,934 20.3 1,908 19.6 2,062 20.9 2,445 23.9 2,479 24.0
≥ 65 2,714 12.1 2,906 12.5 3,218 13.4 4,046 16.5 4,303 17.1
Race/ethnicity
American Indian/Alaska Native 33 3.4 33 3.4 38 3.9 49 4.9 58 5.8
Asianc 73 1.0 72 1.0 92 1.2 88 1.1 102 1.3
Black/African American 4,910 31.2 4,707 29.6 4,800 29.9 5,714 34.9 5,698 34.5
Hispanic/Latinod 2,109 9.3 2,254 9.7 2,201 9.3 2,715 11.1 2,778 11.2
Native Hawaiian/other Pacific Islander 5 2.1 12 5.0 9 3.6 10 3.9 14 5.4
White 4,409 5.2 4,319 5.1 4,486 5.3 4,895 5.8 5,102 6.0
Multiracial 810 36.8 823 36.1 825 34.9 943 38.2 1,127 44.1
Transmission categorye
Male-to-male sexual contactf 7,010 6,888 7,184 8,237 8,672
Injection drug useg 2,154 2,169 2,087 2,427 2,335
Male-to-male sexual contactf
and injection drug useg
1,383 1,453 1,395 1,665 1,687
Heterosexual contacth 1,694 1,600 1,688 1,961 2,071
Perinatali 41 51 41 57 54
Otherj 67 58 59 67 60
Region of residencek
Northeast 2,620 11.3 2,486 10.7 2,604 11.3 3,224 13.5 3,103 13.0
Midwest 1,513 5.4 1,597 5.7 1,574 5.6 1,866 6.5 1,819 6.3
South 5,822 11.6 5,713 11.3 5,880 11.5 6,600 12.7 6,936 13.3
West 2,395 7.5 2,424 7.5 2,396 7.4 2,725 8.3 3,021 9.1
Subtotal 12,350 9.3 12,220 9.1 12,454 9.2 14,415 10.5 14,879 10.8
Female sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 2 0.0 4 0.0 2 0.0 4 0.0 0 0.0
20–24 32 0.3 26 0.2 28 0.3 30 0.3 24 0.2
25–29 98 0.9 74 0.6 66 0.6 100 0.9 93 0.8
30–34 155 1.4 150 1.4 154 1.4 194 1.7 155 1.4
35–39 239 2.3 237 2.2 240 2.2 244 2.2 233 2.1
40–44 311 3.2 327 3.3 294 2.9 328 3.2 335 3.2
45–49 516 4.9 473 4.5 419 4.1 465 4.6 455 4.6
50–54 692 6.4 679 6.4 578 5.6 598 5.7 633 6.0
55–59 721 6.4 675 6.0 644 5.7 755 6.8 844 7.7
60–64 553 5.3 617 5.8 607 5.7 732 6.8 790 7.2
≥ 65 674 2.4 729 2.5 814 2.7 1,187 4.0 1,182 3.9
Race/ethnicity
American Indian/Alaska Native 14 1.4 16 1.6 19 1.9 33 3.2 22 2.1
Asianc 15 0.2 11 0.1 8 0.1 15 0.2 23 0.3
Black/African American 2,283 13.0 2,274 12.8 2,208 12.3 2,613 14.4 2,704 14.8
Hispanic/Latinod 584 2.6 584 2.6 569 2.4 737 3.1 720 3.0
Native Hawaiian/other Pacific Islander 4 1.7 1 0.4 5 2.0 1 0.4 0 0.0
White 825 0.9 831 1.0 770 0.9 859 1.0 923 1.1
Multiracial 267 11.4 274 11.3 266 10.6 379 14.6 351 13.1
Transmission categorye
Injection drug useg 1,373 1,335 1,316 1,494 1,466
Heterosexual contacth 2,548 2,593 2,470 3,060 3,191
Perinatali 43 37 37 45 52
Otherj 29 26 24 38 36
Region of residencek
Northeast 1,073 4.3 1,036 4.2 1,049 4.2 1,298 5.2 1,221 4.9
Midwest 401 1.4 406 1.4 386 1.3 450 1.5 465 1.6
South 2,174 4.1 2,167 4.0 2,036 3.8 2,476 4.6 2,603 4.8
West 345 1.1 382 1.2 375 1.1 413 1.3 455 1.4
Subtotal 3,993 2.9 3,991 2.8 3,846 2.7 4,637 3.3 4,744 3.3
Total 16,343 6.0 16,211 5.9 16,300 5.9 19,052 6.8 19,623 7.0

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 13b. Deaths (any cause) of persons aged ≥ 13 years with diagnosed HIV infection, by year of death, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 1 0.0 0 0.0 0 0.0
15–19 5 0.0 5 0.0 9 0.1 9 0.1 4 0.0
20–24 114 1.0 99 0.9 97 0.9 112 1.0 82 0.7
25–29 351 2.9 353 2.9 374 3.1 363 3.1 373 3.2
30–34 457 4.1 472 4.2 516 4.5 607 5.2 750 6.4
35–39 635 5.9 590 5.4 629 5.7 715 6.3 847 7.5
40–44 687 7.0 656 6.6 671 6.7 831 7.9 867 8.1
45–49 1,267 12.1 1,157 11.2 1,010 9.9 1,067 10.4 1,091 10.9
50–54 2,094 19.7 1,939 18.7 1,728 16.9 1,784 17.0 1,664 15.8
55–59 2,304 21.4 2,310 21.4 2,317 21.5 2,602 23.7 2,569 23.9
60–64 1,963 20.4 1,950 19.9 2,104 21.1 2,481 24.0 2,522 24.1
≥ 65 2,776 12.2 2,980 12.6 3,276 13.4 4,119 16.6 4,390 17.2
Race/ethnicity
American Indian/Alaska Native 33 33 38 49 58
Asianc 73 72 92 89 102
Black/African American 4,914 4,707 4,801 5,715 5,700
Hispanic/Latinod 2,407 2,542 2,472 2,986 3,056
Native Hawaiian/other Pacific Islander 5 13 11 10 14
White 4,410 4,320 4,488 4,897 5,102
Multiracial 810 824 827 943 1,127
Transmission categorye
Male-to-male sexual contactf 7,082 6,967 7,257 8,320 8,730
Injection drug useg 2,286 2,290 2,209 2,534 2,451
Male-to-male sexual contactf
and injection drug useg
1,408 1,475 1,420 1,695 1,714
Heterosexual contacth 1,768 1,663 1,744 2,015 2,149
Perinatali 42 57 43 60 55
Otherj 67 59 59 67 60
Region of residencek
Northeast 2,620 11.3 2,486 10.7 2,604 11.3 3,224 13.5 3,103 13.0
Midwest 1,513 5.4 1,597 5.7 1,574 5.6 1,866 6.5 1,819 6.3
South 5,822 11.6 5,713 11.3 5,880 11.5 6,600 12.7 6,936 13.3
West 2,395 7.5 2,424 7.5 2,396 7.4 2,725 8.3 3,021 9.1
US dependent areas 303 20.0 291 19.8 278 18.8 275 18.1 280 18.4
Subtotal 12,653 9.4 12,511 9.2 12,732 9.3 14,690 10.6 15,159 10.9
Female sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 2 0.0 4 0.0 2 0.0 4 0.0 0 0.0
20–24 33 0.3 26 0.2 28 0.3 30 0.3 24 0.2
25–29 100 0.9 75 0.6 68 0.6 100 0.9 94 0.8
30–34 160 1.5 154 1.4 160 1.4 196 1.7 156 1.4
35–39 243 2.3 243 2.2 246 2.2 248 2.2 237 2.1
40–44 318 3.2 333 3.3 305 3.0 334 3.2 339 3.2
45–49 527 4.9 484 4.6 428 4.1 479 4.7 461 4.6
50–54 710 6.5 692 6.5 591 5.6 609 5.8 638 6.0
55–59 745 6.5 690 6.1 656 5.8 772 6.8 860 7.8
60–64 566 5.4 624 5.8 618 5.7 746 6.8 803 7.3
≥ 65 697 2.4 742 2.5 823 2.7 1,205 4.0 1,214 3.9
Race/ethnicity
American Indian/Alaska Native 14 16 19 33 22
Asianc 15 11 8 15 23
Black/African American 2,284 2,274 2,208 2,615 2,705
Hispanic/Latinod 691 658 647 821 801
Native Hawaiian/other Pacific Islander 4 3 5 1 0
White 825 831 770 859 923
Multiracial 267 274 267 379 351
Transmission categorye
Injection drug useg 1,408 1,368 1,346 1,521 1,486
Heterosexual contacth 2,620 2,634 2,517 3,119 3,253
Perinatali 44 39 38 45 52
Otherj 29 26 25 38 36
Region of residencek
Northeast 1,073 4.3 1,036 4.2 1,049 4.2 1,298 5.2 1,221 4.9
Midwest 401 1.4 406 1.4 386 1.3 450 1.5 465 1.6
South 2,174 4.1 2,167 4.0 2,036 3.8 2,476 4.6 2,603 4.8
West 345 1.1 382 1.2 375 1.1 413 1.3 455 1.4
US dependent areas 108 6.4 76 4.6 79 4.8 86 5.1 82 4.8
Subtotal 4,101 2.9 4,067 2.9 3,925 2.8 4,723 3.3 4,826 3.4
Total 16,754 6.1 16,578 6.0 16,657 6.0 19,413 6.9 19,985 7.1

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.

Table 14a. Deaths (any cause) of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 2 1 5 7 5
25–29 8 12 17 17 12
30–34 9 9 19 30 41
35–39 15 13 17 29 29
40–44 12 12 17 23 27
45–49 19 12 17 26 15
50–54 11 19 17 21 20
55–59 19 18 17 25 30
60–64 7 11 12 14 20
≥ 65 6 11 7 15 16
Race/ethnicity
American Indian/Alaska Native 0 2 1 4 5
Asianb 0 2 1 3 2
Black/African American 45 46 69 106 99
Hispanic/Latinoc 36 34 33 52 58
Native Hawaiian/other Pacific Islander 1 0 0 1 0
White 18 21 24 23 26
Multiracial 8 13 17 18 25
Exposure categoryd
Sexual contacte 79 78 99 144 159
Injection drug usef 0 0 1 2 0
Sexual contacte
and injection drug usef
26 38 39 56 49
Otherg 3 2 6 5 7
Region of residenceh
Northeast 26 32 39 61 56
Midwest 11 11 22 22 27
South 41 43 55 72 75
West 30 32 29 52 57
Subtotal 108 118 145 207 215
Transgender mana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 1 0
25–29 0 0 1 1 0
30–34 1 0 0 1 0
35–39 0 0 0 1 0
40–44 0 0 0 2 0
45–49 1 2 0 1 0
50–54 0 1 1 0 0
55–59 2 1 1 1 1
60–64 0 0 2 1 1
≥ 65 1 1 0 1 0
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 3 0 1 3 1
Hispanic/Latinoc 1 2 2 2 1
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 0 2 1 2 0
Multiracial 1 1 1 3 0
Exposure categoryd
Sexual contacte 3 0 3 6 0
Injection drug usef 0 0 0 0 0
Sexual contacte
and injection drug usef
2 5 1 4 2
Otherg 0 0 1 0 0
Region of residenceh
Northeast 1 0 1 2 1
Midwest 0 1 1 1 0
South 3 3 3 4 1
West 1 1 0 3 0
Subtotal 5 5 5 10 2
Additional gender identityi
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 0
25–29 0 0 0 0 0
30–34 2 0 0 0 0
35–39 0 0 0 0 0
40–44 0 0 1 0 0
45–49 0 0 0 0 0
50–54 0 0 0 0 0
55–59 1 1 0 0 0
60–64 0 0 0 0 1
≥ 65 0 0 1 0 0
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 1 0 2 0 0
Hispanic/Latinoc 1 1 0 0 0
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 1 0 0 0 0
Multiracial 0 0 0 0 1
Exposure categoryd
Sexual contacte 2 0 1 0 1
Injection drug usef 0 0 0 0 0
Sexual contacte
and injection drug usef
1 1 1 0 0
Otherg 0 0 0 0 0
Region of residenceh
Northeast 1 0 1 0 1
Midwest 1 0 1 0 0
South 1 0 0 0 0
West 0 1 0 0 0
Subtotal 3 1 2 0 1
Total 116 124 152 217 218

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 14b. Deaths (any cause) of transgender and additional gender identity persons aged ≥ 13 years with diagnosed HIV infection, by year of death and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 2 1 5 7 5
25–29 8 12 17 17 12
30–34 9 9 19 30 41
35–39 16 13 17 29 30
40–44 12 12 17 23 27
45–49 19 12 18 26 15
50–54 12 19 17 22 20
55–59 19 18 17 25 30
60–64 7 11 12 14 20
≥ 65 6 12 8 15 16
Race/ethnicity
American Indian/Alaska Native 0 2 1 4 5
Asianb 0 2 1 3 2
Black/African American 45 46 69 106 99
Hispanic/Latinoc 38 35 35 53 59
Native Hawaiian/other Pacific Islander 1 0 0 1 0
White 18 21 24 23 26
Multiracial 8 13 17 18 25
Exposure categoryd
Sexual contacte 79 79 99 145 159
Injection drug usef 0 0 1 2 0
Sexual contacte
and injection drug usef
28 38 41 56 50
Otherg 3 2 6 5 7
Region of residenceh
Northeast 26 32 39 61 56
Midwest 11 11 22 22 27
South 41 43 55 72 75
West 30 32 29 52 57
US dependent areas 2 1 2 1 1
Subtotal 110 119 147 208 216
Transgender mana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 1 0
25–29 0 0 1 1 0
30–34 1 0 0 1 0
35–39 0 0 0 1 0
40–44 0 0 0 2 0
45–49 1 2 0 1 0
50–54 0 1 1 0 0
55–59 2 1 1 1 1
60–64 0 0 2 1 1
≥ 65 1 1 0 1 0
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 3 0 1 3 1
Hispanic/Latinoc 1 2 2 2 1
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 0 2 1 2 0
Multiracial 1 1 1 3 0
Exposure categoryd
Sexual contacte 3 0 3 6 0
Injection drug usef 0 0 0 0 0
Sexual contacte
and injection drug usef
2 5 1 4 2
Otherg 0 0 1 0 0
Region of residenceh
Northeast 1 0 1 2 1
Midwest 0 1 1 1 0
South 3 3 3 4 1
West 1 1 0 3 0
US dependent areas 0 0 0 0 0
Subtotal 5 5 5 10 2
Additional gender identityi
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 0
25–29 0 0 0 0 0
30–34 2 0 0 0 0
35–39 0 0 0 0 0
40–44 0 0 1 0 0
45–49 0 0 0 0 0
50–54 0 0 0 0 0
55–59 1 1 0 0 0
60–64 0 0 0 0 1
≥ 65 0 0 1 0 0
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 1 0 2 0 0
Hispanic/Latinoc 1 1 0 0 0
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 1 0 0 0 0
Multiracial 0 0 0 0 1
Exposure categoryd
Sexual contacte 2 0 1 0 1
Injection drug usef 0 0 0 0 0
Sexual contacte
and injection drug usef
1 1 1 0 0
Otherg 0 0 0 0 0
Region of residenceh
Northeast 1 0 1 0 1
Midwest 1 0 1 0 0
South 1 0 0 0 0
West 0 1 0 0 0
US dependent areas 0 0 0 0 0
Subtotal 3 1 2 0 1
Total 118 125 154 218 219

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Death data for years 2020 and 2021 should be interpreted with caution due to excess deaths in the United States population attributed to the COVID-19 pandemic. For additional information, see https://www.cdc.gov/nchs/nvss/vsrr/covid19/excess_deaths.htm. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥13 years are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Other risk factors, including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
h Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used; when both residence at death and state where a person’s death occurred were not available, the most recent known address on or before the date of death is used.
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 749,255 767,894 785,712 796,670 812,192
Female 235,211 238,870 242,488 243,646 246,029
Transgender woman/girlb 10,775 11,347 11,937 12,447 13,111
Transgender man/boyb 401 448 490 520 574
Additional gender identityc 239 260 292 315 361
Age at end of year
< 13 2,058 3.9 1,897 3.6 1,670 3.2 1,445 2.8 1,262 2.4
13–14 670 8.1 667 8.0 652 7.8 639 7.3 599 6.7
15–19 4,548 21.5 4,367 20.7 4,251 20.2 3,800 17.6 3,689 17.1
20–24 28,433 128.9 27,005 123.7 26,064 120.4 24,267 113.0 23,768 110.4
25–29 70,343 301.1 70,846 300.9 69,328 294.5 65,558 287.5 62,673 279.9
30–34 82,697 376.6 87,652 396.0 93,088 414.4 97,085 424.4 100,758 436.1
35–39 91,538 432.0 93,448 433.7 95,421 438.6 96,667 434.8 100,231 449.5
40–44 95,663 488.7 96,353 489.5 97,899 491.4 100,213 484.8 102,963 487.9
45–49 129,431 619.4 122,787 592.7 116,648 572.1 108,962 536.3 104,701 529.3
50–54 162,116 760.0 156,876 752.2 150,087 733.2 144,716 696.3 138,428 662.1
55–59 143,636 654.5 152,013 693.6 159,310 728.4 162,057 735.4 162,000 751.1
60–64 95,574 479.6 103,683 510.7 111,536 542.5 119,583 568.4 127,237 599.2
≥ 65 89,174 175.7 101,225 193.3 114,965 212.8 128,606 236.2 143,958 257.8
Race/ethnicity
American Indian/Alaska Native 2,759 115.1 2,882 119.6 3,020 124.7 3,130 128.0 3,276 133.6
Asiand 13,730 74.8 14,605 78.0 15,360 80.5 15,974 81.9 16,720 84.9
Black/African American 403,102 993.1 412,368 1008.3 421,362 1022.9 426,145   1,021.3 432,958 1,034.3
Hispanic/Latinoe 226,093 387.1 234,034 393.5 242,008 400.6 247,235 399.5 255,281 407.5
Native Hawaiian/other Pacific Islander 745 127.9 790 133.1 836 138.4 889 143.7 955 152.5
White 292,874 148.1 297,228 150.5 301,145 152.7 303,326 153.4 306,583 155.8
Multiracial 55,893 798.0 56,227 781.8 56,507 766.1 56,219 737.5 55,816 716.4
Transmission categoryf
Male sex at birth (≥ 13 yrs at end of year)g
Male-to-male sexual contacth 549,064 567,472 585,215 598,237 615,019
Injection drug usei 67,773 67,101 66,494 65,327 64,530
Male-to-male sexual contacth
and injection drug usei
58,001 58,116 58,324 57,858 57,559
Heterosexual contactj 76,847 78,210 79,292 79,440 79,991
Perinatalk 4,814 4,912 5,037 5,120 5,217
Otherl 2,767 2,753 2,755 2,737 2,733
Subtotal 759,266 570.1 778,564 580.6 797,117 590.5 808,719 588.8 825,049 598.1
Female sex at birth (≥ 13 yrs at end of year)g
Injection drug usei 49,011 48,850 48,759 48,197 47,864
Heterosexual contactj 178,387 182,152 185,832 187,561 190,265
Perinatalk 5,518 5,697 5,858 5,979 6,120
Otherl 1,641 1,659 1,684 1,697 1,707
Subtotal 234,557 168.5 238,358 170.0 242,132 171.6 243,434 171.9 245,956 172.9
Child (< 13 yrs at end of year)
Perinatal 1,713 1,562 1,382 1,209 1,060
Otherl 345 335 288 236 202
Subtotal 2,058 3.9 1,897 3.6 1,670 3.2 1,445 2.8 1,262 2.4
Region of residencem
Northeast 231,318 412.5 233,355 416.1 234,829 419.3 234,339 407.4 235,158 411.4
Midwest 118,715 174.2 121,808 178.4 124,536 182.2 126,494 183.5 129,138 187.6
South 449,380 363.5 461,770 370.5 474,428 377.5 482,397 381.6 493,509 387.9
West 196,468 254.3 201,886 259.4 207,126 264.5 210,368 267.5 214,462 272.6
Totaln 995,881 306.3 1,018,819 311.7 1,040,919 317.0 1,053,598 317.8 1,072,267 323.1

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at the end of the specified year (i.e., most recent known address).
n Includes persons whose race/ethnicity is unknown.

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 760,803 779,369 797,263 808,207 823,824
Female 240,162 243,758 247,371 248,484 250,857
Transgender woman/girlb 10,814 11,385 11,978 12,491 13,150
Transgender man/boyb 404 451 493 523 577
Additional gender identityc 239 261 292 315 361
Age at end of year
< 13 2,067 3.9 1,903 3.6 1,675 3.2 1,448 2.7 1,266 2.4
13–14 676 8.1 675 8.0 656 7.8 642 7.2 601 6.7
15–19 4,594 21.5 4,410 20.7 4,277 20.1 3,822 17.6 3,707 17.0
20–24 28,729 128.7 27,275 123.6 26,319 120.2 24,487 112.8 23,959 110.0
25–29 71,050 300.9 71,544 300.7 70,016 294.3 66,172 287.0 63,270 279.4
30–34 83,610 377.1 88,530 396.4 93,994 414.6 97,999 424.2 101,666 435.7
35–39 92,825 433.4 94,626 434.8 96,498 439.3 97,690 435.3 101,254 449.9
40–44 97,251 491.0 97,870 491.7 99,356 493.3 101,638 486.4 104,375 489.3
45–49 131,618 622.6 124,765 595.6 118,507 574.7 110,642 538.4 106,287 531.2
50–54 165,046 764.7 159,691 756.8 152,693 737.3 147,229 700.3 140,770 665.7
55–59 146,286 659.2 154,756 698.4 162,214 733.5 164,931 740.0 164,852 755.6
60–64 97,425 483.3 105,704 514.8 113,673 546.8 121,871 572.7 129,622 603.6
≥ 65 91,245 177.3 103,475 195.0 117,519 214.6 131,449 238.1 147,140 259.8
Race/ethnicity
American Indian/Alaska Native 2,761 2,884 3,022 3,132 3,278
Asiand 13,786 14,665 15,427 16,041 16,788
Black/African American 403,402 412,682 421,683 426,472 433,293
Hispanic/Latinoe 242,128 249,919 257,943 263,102 271,212
Native Hawaiian/other Pacific Islander 778 822 869 923 989
White 292,960 297,313 301,240 303,423 306,688
Multiracial 55,919 56,251 56,529 56,244 55,839
Transmission categoryf
Male sex at birth (≥ 13 yrs at end of year)g
Male-to-male sexual contacth 553,853 572,368 590,283 603,437 620,421
Injection drug usei 71,241 70,441 69,734 68,468 67,586
Male-to-male sexual contacth
and injection drug usei
58,804 58,890 59,089 58,604 58,297
Heterosexual contactj 79,212 80,556 81,654 81,781 82,317
Perinatalk 4,943 5,040 5,166 5,245 5,337
Otherl 2,795 2,780 2,782 2,763 2,759
Subtotal 770,848 572.3 790,075 582.7 808,707 592.6 820,299 590.7 836,718 600.0
Female sex at birth (≥ 13 yrs at end of year)g
Injection drug usei 50,003 49,809 49,704 49,119 48,764
Heterosexual contactj 182,209 185,953 189,650 191,356 194,074
Perinatalk 5,641 5,813 5,966 6,090 6,227
Otherl 1,654 1,671 1,694 1,708 1,720
Subtotal 239,507 170.0 243,246 171.5 247,015 173.1 248,273 173.2 250,785 174.2
Child (< 13 yrs at end of year)
Perinatal 1,722 1,568 1,387 1,212 1,064
Otherl 345 335 288 236 202
Subtotal 2,067 3.9 1,903 3.6 1,675 3.2 1,448 2.7 1,266 2.4
Region of residencem
Northeast 231,318 412.5 233,355 416.1 234,829 419.3 234,339 407.4 235,158 411.4
Midwest 118,715 174.2 121,808 178.4 124,536 182.2 126,494 183.5 129,138 187.6
South 449,380 363.5 461,770 370.5 474,428 377.5 482,397 381.6 493,509 387.9
West 196,468 254.3 201,886 259.4 207,126 264.5 210,368 267.5 214,462 272.6
U.S. dependent areas 16,541 444.2 16,405 456.8 16,478 459.0 16,422 446.6 16,502 451.1
Totaln 1,012,422 307.9 1,035,224 313.3 1,057,397 318.6 1,070,020 319.2 1,088,769 324.5

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at the end of the specified year (i.e., most recent known address).
n Includes persons whose race/ethnicity is unknown.

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2021—United States
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated
Gender
Male 2,411 13,594 283,953 204,798 763 264,430 41,758 812,192
Female 796 2,890 142,524 45,945 153 40,562 12,966 246,029
Transgender woman/girle 64 219 6,106 4,311 39 1,370 1,002 13,111
Transgender man/boye 4 11 234 130 0 142 53 574
Additional gender identityf 1 6 141 97 0 79 37 361
Age at end of year 
< 13 6 1.5 88 3.1 731 10.2 180 1.3 3 2.6 155 0.6 99 3.9 1,262 2.4
13–14 1 1.3 39 8.7 338 27.5 81 3.5 0 0.0 88 2.0 52 13.7 599 6.7
15–19 19 10.5 108 9.5 2,171 74.2 766 14.3 8 18.5 417 3.7 200 24.4 3,689 17.1
20–24 88 48.7 376 30.9 13,224 437.5 5,909 119.1 27 63.2 3,118 27.4 1,021 143.8 23,768 110.4
25–29 270 142.5 1,160 79.5 30,983 946.5 16,750 344.7 71 150.0 10,225 85.6 3,208 518.2 62,673 279.9
30–34 394 210.5 1,860 110.0 47,548 1450.8 25,990 549.9 126 234.5 19,220 151.7 5,614 1131.0 100,758 436.1
35–39 391 237.9 1,953 116.1 42,427 1480.5 27,860 604.2 124 239.0 21,900 174.9 5,569 1393.7 100,231 449.5
40–44 380 252.1 2,038 134.2 41,304 1525.0 29,189 665.9 129 284.9 24,185 202.3 5,723 1667.4 102,963 487.9
45–49 318 229.1 2,348 161.6 41,266 1652.8 29,001 730.0 101 262.6 26,078 228.7 5,562 1979.5 104,701 529.3
50–54 458 317.7 2,290 175.1 51,427 1998.0 34,138 960.3 110 298.8 42,454 325.8 7,465 2901.8 138,428 662.1
55–59 397 258.3 1,771 151.8 58,932 2251.4 34,884 1135.0 100 280.9 57,324 401.3 8,440 3574.7 162,000 751.1
60–64 281 190.0 1,133 108.5 48,019 1961.2 24,471 995.8 73 231.2 46,754 314.0 6,359 2914.3 127,237 599.2
≥ 65 273 83.2 1,556 57.7 54,588 1034.4 26,062 516.2 83 122.6 54,665 130.3 6,504 1368.1 143,958 257.8
Transmission categoryg
Male sex at birth (≥ 13 yrs at end of year)h
Male-to-male sexual contacti 1,773 11,670 192,625 159,035 683 217,222 31,683 615,019
Injection drug usej 225 463 29,182 18,423 24 13,440 2,699 64,530
Male-to-male sexual contacti
and injection drug usej
293 436 15,249 13,539 52 23,373 4,573 57,559
Heterosexual contactk 164 1,078 49,028 16,450 37 9,915 3,292 79,991
Perinatall 6 66 2,969 1,241 3 574 350 5,217
Otherm 14 67 793 430 1 1,274 150 2,733
Subtotal 2,474 247.3 13,780 172.7 289,847 1756.8 209,118 839.6 800 309.7 265,798 313.6 42,747 1673.0 825,049 598.1
Female sex at birth (≥ 13 yrs at end of year)h
Injection drug usej 270 192 22,134 9,349 27 12,783 3,047 47,864
Heterosexual contactk 509 2,511 115,867 34,984 125 26,736 9,416 190,265
Perinatall 9 77 3,584 1,384 0 638 419 6,120
Otherm 8 71 795 267 1 473 87 1,707
Subtotal 796 76.5 2,852 32.3 142,380 781.6 45,983 188.6 152 59.9 40,630 46.8 12,970 483.6 245,956 172.9
Child (< 13 yrs at end of year)
Perinatal 5 51 621 165 3 124 91 1,060
Otherm 1 37 110 15 0 31 8 202
Subtotal 6 1.5 88 3.1 731 10.2 180 1.3 3 2.6 155 0.6 99 3.9 1,262 2.4
Region of residencen
Northeast 145 109.0 3,571 88.2 88,954 1,366.9 73,702 840.5 66 284.4 53,270 145.5 15,118 1,428.2 235,158 411.4
Midwest 417 99.4 1,618 65.8 54,575 747.9 16,755 287.0 52 126.7 48,522 94.6 7,116 476.1 129,138 187.6
South 803 97.3 3,600 75.3 255,815 1,047.8 89,718 375.2 167 161.2 119,022 168.7 24,228 926.4 493,509 387.9
West 1,911 177.9 7,931 94.5 33,614 923.7 75,106 311.3 670 146.2 85,769 223.6 9,354 356.7 214,462 272.6
Total 3,276 133.6 16,720 84.9 432,958 1034.3 255,281 407.5 955 152.5 306,583 155.8 55,816 716.4 1,072,267 323.1

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
h Data include transgender and additional gender identity persons.
i Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
j Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
k Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
l Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
m Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
n Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2021—United States and 6 dependent areas
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. No. No. No. No. No. No. No.
Gender
Male 2,413 13,651 284,157 216,034 789 264,516 41,776 823,824
Female 796 2,901 142,655 50,599 160 40,581 12,971 250,857
Transgender woman/girld 64 219 6,106 4,349 40 1,370 1,002 13,150
Transgender man/boyd 4 11 234 133 0 142 53 577
Additional gender identitye 1 6 141 97 0 79 37 361
Age at end of year
< 13 6 88 732 182 4 155 99 1,266
13–14 1 39 338 83 0 88 52 601
15–19 19 108 2,173 781 8 417 201 3,707
20–24 88 376 13,230 6,092 28 3,118 1,022 23,959
25–29 270 1,160 30,988 17,338 73 10,226 3,209 63,270
30–34 394 1,867 47,563 26,864 132 19,226 5,614 101,666
35–39 391 1,960 42,444 28,844 128 21,911 5,569 101,254
40–44 380 2,046 41,326 30,555 135 24,191 5,727 104,375
45–49 318 2,356 41,303 30,531 102 26,086 5,563 106,287
50–54 459 2,296 51,485 36,388 114 42,471 7,470 140,770
55–59 397 1,781 58,982 37,651 103 57,343 8,443 164,852
60–64 282 1,147 48,064 26,772 77 46,773 6,360 129,622
≥ 65 273 1,564 54,665 29,131 85 54,683 6,510 147,140
Transmission categoryf
Male sex at birth (≥ 13 yrs at end of year)g
Male-to-male sexual contacth 1,774 11,716 192,718 164,187 704 217,295 31,698 620,421
Injection drug usei 225 469 29,219 21,432 24 13,444 2,700 67,586
Male-to-male sexual contacth
and injection drug usei
293 438 15,255 14,260 54 23,379 4,575 58,297
Heterosexual contactj 165 1,082 49,093 18,700 40 9,919 3,293 82,317
Perinatalk 6 66 2,971 1,358 3 574 350 5,337
Otherl 14 67 793 455 1 1,274 150 2,759
Subtotal 2,476 13,837 290,050 220,391 827 265,884 42,765 836,718
Female sex at birth (≥ 13 yrs at end of year)g
Injection drug usei 270 194 22,149 10,225 27 12,789 3,048 48,764
Heterosexual contactj 509 2,520 115,977 38,653 130 26,748 9,419 194,074
Perinatalk 9 77 3,589 1,485 1 638 421 6,227
Otherl 8 71 797 277 1 473 87 1,720
Subtotal 796 2,863 142,511 50,639 158 40,649 12,975 250,785
Child (< 13 yrs at end of year)
Perinatal 5 51 622 167 4 124 91 1,064
Otherl 1 37 110 15 0 31 8 202
Subtotal 6 88 732 182 4 155 99 1,266
Region of residencem
Northeast 145 3,571 88,954 73,702 66 53,270 15,118 235,158
Midwest 417 1,618 54,575 16,755 52 48,522 7,116 129,138
South 803 3,600 255,815 89,718 167 119,022 24,228 493,509
West 1,911 7,931 33,614 75,106 670 85,769 9,354 214,462
U.S. dependent areas 2 68 335 15,931 34 105 23 16,502
Total 3,278 16,788 433,293 271,212 989 306,688 55,839 1,088,769

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12 should be interpreted with caution.

a Includes Asian/Pacific Islander legacy cases (see Technical Notes).
b Hispanic/Latino persons can be of any race.
c Includes persons whose race/ethnicity is unknown.
d “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
e Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Data include transgender and additional gender identity persons.
h Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
i Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
j Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
k Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
l Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
m Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 17a. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, assigned sex at birth, and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at end of year
13–14 301 7.1 298 7.0 308 7.2 311 6.9 300 6.6
15–19 2,983 27.7 2,883 26.8 2,858 26.6 2,500 22.7 2,415 21.9
20–24 23,174 204.8 22,111 197.9 21,436 193.7 20,106 183.7 19,861 181.0
25–29 58,974 495.7 59,659 496.7 58,647 487.9 55,563 479.8 53,173 467.3
30–34 66,180 597.2 71,477 639.0 76,816 675.6 80,964 699.6 84,810 726.5
35–39 67,930 641.0 70,429 653.2 73,075 670.9 75,449 672.1 79,475 705.6
40–44 67,581 695.4 68,345 698.7 70,274 709.4 72,880 702.9 75,872 716.2
45–49 94,975 917.6 89,349 871.8 83,910 832.2 77,639 764.4 74,209 751.4
50–54 124,484 1,187.2 119,594 1,165.3 113,494 1,125.7 108,467 1,046.0 102,890 985.9
55–59 110,421 1,034.8 117,086 1,098.5 122,778 1,154.0 124,826 1,149.7 124,456 1,170.8
60–64 73,334 769.6 79,273 815.8 85,115 864.0 91,286 892.2 97,331 941.9
≥ 65 68,929 306.1 78,060 335.4 88,406 367.4 98,728 402.4 110,257 437.3
Race/ethnicity
American Indian/Alaska Native 2,031 212.1 2,139 221.4 2,252 231.0 2,353 237.2 2,474 247.3
Asianc 11,210 153.0 11,965 159.7 12,605 164.8 13,127 166.7 13,780 172.7
Black/African American 265,465 1,686.5 272,692 1,715.9 279,785 1,743.9 284,122 1,734.2 289,847 1,756.8
Hispanic/Latinod 182,348 805.4 189,522 818.7 196,749 832.8 201,717 825.6 209,118 839.6
Native Hawaiian/other Pacific Islander 619 261.2 662 273.6 706 286.0 744 292.6 800 309.7
White 254,576 302.8 258,273 307.2 261,441 310.9 263,168 309.8 265,798 313.6
Multiracial 42,527 1,929.5 42,821 1,877.2 43,092 1,824.8 43,002 1,742.0 42,747 1,673.0
Transmission categorye
   Male-to-male sexual contactf 549,064 567,472 585,215 598,237 615,019
   Injection drug useg 67,773 67,101 66,494 65,327 64,530
   Male-to-male sexual contactf
and injection drug useg
58,001 58,116 58,324 57,858 57,559
   Heterosexual contacth 76,847 78,210 79,292 79,440 79,991
   Perinatali 4,814 4,912 5,037 5,120 5,217
   Otherj 2,767 2,753 2,755 2,737 2,733
Region of residencek
Northeast 163,299 707.0 165,156 714.1 166,690 720.8 166,706 696.6 167,785 703.6
Midwest 93,749 335.1 96,200 342.8 98,302 349.3 99,911 349.3 102,097 356.3
South 330,995 660.0 341,278 673.9 351,614 687.4 358,763 692.2 368,312 704.1
West 171,223 536.0 175,930 545.1 180,511 554.3 183,339 556.0 186,855 564.0
Subtotal 759,266 570.1 778,564 580.6 797,117 590.5 808,719 588.8 825,049 598.1
Female sex at birthb
Age at end of year 
13–14 369 9.1 369 9.1 344 8.4 328 7.7 299 6.9
15–19 1,565 15.2 1,484 14.4 1,393 13.5 1,300 12.3 1,274 12.1
20–24 5,259 48.9 4,894 45.9 4,628 43.8 4,161 39.5 3,907 37.0
25–29 11,369 99.2 11,187 97.0 10,681 92.7 9,995 89.0 9,500 86.3
30–34 16,517 151.9 16,175 147.8 16,272 146.7 16,121 142.6 15,948 139.5
35–39 23,608 222.8 23,019 213.8 22,346 205.7 21,218 192.8 20,756 188.1
40–44 28,082 284.9 28,008 282.9 27,625 275.9 27,333 265.3 27,091 257.7
45–49 34,456 326.7 33,438 319.5 32,738 317.6 31,323 308.3 30,492 307.8
50–54 37,632 347.0 37,282 351.9 36,593 352.3 36,249 348.1 35,538 339.4
55–59 33,215 294.6 34,927 310.2 36,532 325.2 37,231 333.1 37,544 343.3
60–64 22,240 213.9 24,410 230.6 26,421 246.7 28,297 261.8 29,906 274.3
≥ 65 20,245 71.7 23,165 79.7 26,559 88.6 29,878 99.9 33,701 110.0
Race/ethnicity
American Indian/Alaska Native 722 72.1 737 72.9 762 74.6 770 74.7 796 76.5
Asianc 2,406 29.2 2,531 30.0 2,646 30.8 2,747 31.5 2,852 32.3
Black/African American 136,404 774.3 138,566 779.5 140,606 783.8 141,187 780.4 142,380 781.6
Hispanic/Latinod 43,472 194.8 44,258 193.7 45,035 193.0 45,323 189.6 45,983 188.6
Native Hawaiian/other Pacific Islander 123 52.4 126 52.6 128 52.4 142 56.9 152 59.9
White 38,048 43.5 38,714 44.3 39,494 45.2 39,976 45.9 40,630 46.8
Multiracial 13,187 561.8 13,231 546.0 13,267 530.3 13,095 504.2 12,970 483.6
Transmission categorye
   Injection drug useg 49,011 48,850 48,759 48,198 47,864
   Heterosexual contacth 178,387 182,152 185,832 187,561 190,265
   Perinatali 5,518 5,697 5,858 5,979 6,120
   Otherj 1,641 1,659 1,684 1,697 1,707
Region of residencek
Northeast 67,699 274.2 67,927 275.0 67,894 275.0 67,428 267.8 67,192 268.0
Midwest 24,497 84.2 25,146 86.2 25,835 88.3 26,233 89.5 26,742 91.1
South 117,446 221.6 119,631 223.4 122,055 225.6 122,969 227.2 124,610 227.9
West 24,915 76.8 25,654 78.3 26,348 79.7 26,804 81.2 27,412 82.6
Subtotal 234,557 168.5 238,358 170.0 242,132 171.6 243,434 171.9 245,956 172.9
Total 993,823 364.8 1,016,922 370.8 1,039,249 376.5 1,052,153 377.1 1,071,005 382.2

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 17b. Persons aged ≥ 13 years living with diagnosed HIV infection, by year, assigned sex at birth, and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at end of year 
13–14 303 7.1 302 7.0 311 7.2 313 6.9 301 6.6
15–19 3,007 27.6 2,911 26.7 2,875 26.4 2,514 22.6 2,426 21.8
20–24 23,402 204.4 22,314 197.5 21,639 193.4 20,287 183.2 20,013 180.3
25–29 59,536 495.2 60,224 496.4 59,207 487.5 56,059 478.8 53,671 466.5
30–34 66,862 597.8 72,149 639.4 77,522 675.7 81,692 699.3 85,548 725.7
35–39 68,831 642.9 71,261 654.7 73,861 671.9 76,221 673.0 80,259 706.4
40–44 68,666 698.6 69,398 701.9 71,300 712.2 73,877 705.2 76,866 718.3
45–49 96,474   921.8 90,669 875.1 85,137 835.3 78,767 767.1 75,282 754.0
50–54 126,550 1,193.5 121,608 1,171.9 115,351 1,131.4 110,249 1,051.6 104,521   990.7
55–59 112,232 1,040.7 118,983 1,104.6 124,796 1,160.7 126,831 1,155.8 126,481 1,177.0
60–64 74,637 774.7 80,658 821.1 86,562 869.3 92,826 897.6 98,927 947.3
≥ 65 70,348 308.2 79,598 337.5 90,146 369.8 100,663 404.8 112,423 439.9
Race/ethnicity
American Indian/Alaska Native 2,033 2,141 2,254 2,355 2,476
Asianc 11,255 12,014 12,661 13,183 13,837
Black/African American 265,638 272,879 279,975 284,317 290,050
Hispanic/Latinod 193,594 200,681 207,968 212,915 220,391
Native Hawaiian/other Pacific Islander 644 688 732 771 827
White 254,644 258,341 261,518 263,248 265,884
Multiracial 42,548 42,839 43,110 43,022 42,765
Transmission categorye
Male-to-male sexual contactf 553,853 572,368 590,282 603,437 620,421
Injection drug useg 71,241 70,441 69,734 68,468 67,586
Male-to-male sexual contactf
and injection drug useg
58,805 58,890 59,089 58,605 58,297
Heterosexual contacth 79,212 80,556 81,654 81,781 82,317
Perinatali 4,943 5,040 5,166 5,245 5,337
Otherj 2,795 2,780 2,782 2,763 2,759
Region of residencek
Northeast 163,299 707.0 165,156 714.1 166,690 720.8 166,706 696.6 167,785 703.6
Midwest 93,749 335.1 96,200 342.8 98,302 349.3 99,911 349.3 102,097 356.3
South 330,995 660.0 341,278 673.9 351,614 687.4 358,763 692.2 368,312 704.1
West 171,223 536.0 175,930 545.1 180,511 554.3 183,339 556.0 186,855 564.0
U.S. dependent areas 11,582 765.7 11,511 782.4 11,590 784.3 11,580 761.2 11,669 767.5
Subtotal 770,848 572.3 790,075 582.7 808,707 592.6 820,299 590.7 836,718 600.0
Female sex at birthb
Age at end of year
13–14 373 9.1 373 9.1 345 8.4 329 7.6 300 6.9
15–19 1,587 15.2 1,499 14.4 1,402 13.4 1,308 12.3 1,281 12.0
20–24 5,327 49.0 4,961 46.0 4,680 43.7 4,200 39.5 3,946 37.0
25–29 11,514 99.3 11,320 97.1 10,809 92.8 10,113 89.1 9,599 86.2
30–34 16,748 152.4 16,381 148.2 16,472 147.1 16,307 142.8 16,118 139.6
35–39 23,994 223.9 23,365 214.7 22,637 206.3 21,469 193.1 20,995 188.4
40–44 28,585 286.5 28,472 284.2 28,056 277.0 27,761 266.4 27,509 258.8
45–49 35,144 329.3 34,096 322.0 33,370 320.0 31,875 310.0 31,005 309.3
50–54 38,496 350.6 38,083 355.2 37,342 355.2 36,980 350.8 36,249 342.1
55–59 34,054 298.6 35,773 314.1 37,418 329.3 38,100 336.7 38,371 346.6
60–64 22,788 216.5 25,046 233.9 27,111 250.3 29,045 265.5 30,695 278.2
≥ 65 20,897 73.0 23,877 81.0 27,373 90.1 30,786 101.5 34,717 111.7
Race/ethnicity
American Indian/Alaska Native 722 737 762 770 796
Asianc 2,417 2,542 2,657 2,758 2,863
Black/African American 136,530 138,692 140,736 141,318 142,511
Hispanic/Latinod 48,254 48,980 49,748 49,991 50,639
Native Hawaiian/other Pacific Islander 130 131 134 148 158
White 38,066 38,731 39,512 39,993 40,649
Multiracial 13,192 13,237 13,271 13,100 12,975
Transmission categorye
Injection drug useg 50,003 49,809 49,704 49,119 48,764
Heterosexual contacth 182,209 185,953 189,650 191,356 194,074
Perinatali 5,641 5,813 5,966 6,090 6,227
Otherj 1,654 1,671 1,694 1,708 1,720
Region of residencek
Northeast 67,699 274.2 67,927 275.0 67,894 275.0 67,428 267.8 67,192 268.0
Midwest 24,497 84.2 25,146 86.2 25,835 88.3 26,233 89.5 26,742 91.1
South 117,446 221.6 119,631 223.4 122,055 225.6 122,969 227.2 124,610 227.9
West 24,915 76.8 25,654 78.3 26,348 79.7 26,804 81.2 27,412 82.6
U.S. dependent areas 4,950 294.0 4,888 298.7 4,883 296.8 4,839 285.1 4,829 284.1
Subtotal 239,507 170.0 243,246 171.5 247,015 173.1 248,273 173.2 250,785 174.2
Total 1,010,355 366.6 1,033,321 372.5 1,055,722 378.1 1,068,572 378.7 1,087,503 383.7

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.

a Rates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
b Data include transgender and additional gender identity persons.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on residence at the end of the specified year (i.e., most recent known address).

Table 18a. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at end of year 
13–14 0 0 0 1 2
15–19 106 78 76 53 64
20–24 864 837 802 774 786
25–29 2,002 2,005 1,928 1,846 1,833
30–34 1,891 2,115 2,380 2,620 2,749
35–39 1,519 1,628 1,758 1,840 2,015
40–44 1,150 1,227 1,314 1,451 1,605
45–49 1,117 1,132 1,173 1,168 1,191
50–54 1,010 1,056 1,055 1,105 1,123
55–59 625 703 795 830 876
60–64 314 355 392 455 521
≥ 65 175 209 262 303 345
Race/ethnicity
American Indian/Alaska Native 44 51 55 59 64
Asianb 166 176 188 201 219
Black/African American 5,029 5,305 5,581 5,816 6,106
Hispanic/Latinoc 3,436 3,642 3,870 4,062 4,311
Native Hawaiian/other Pacific Islander 24 27 31 33 39
White 1,124 1,174 1,232 1,284 1,370
Multiracial 950 970 978 991 1,001
Exposure categoryd
Sexual contacte 8,923 9,467 10,027 10,529 11,151
Injection drug usef 22 26 27 27 30
Sexual contacte
and injection drug usef
1,646 1,663 1,682 1,670 1,679
Perinatalg 24 24 23 23 22
Otherh 158 165 176 197 228
Region of residencei
Northeast 2,786 2,928 3,039 3,126 3,256
Midwest 1,497 1,601 1,655 1,741 1,862
South 3,937 4,114 4,339 4,577 4,830
West 2,553 2,702 2,902 3,002 3,162
Subtotal 10,773 11,345 11,935 12,446 13,110
Transgender mana
Age at end of year 
13–14 1 0 0 1 2
15–19 7 7 5 3 6
20–24 20 22 29 39 40
25–29 63 75 75 69 70
30–34 45 63 88 99 123
35–39 66 66 67 76 83
40–44 41 51 55 56 62
45–49 49 52 53 48 48
50–54 48 47 45 48 47
55–59 28 25 34 39 45
60–64 21 27 23 25 23
≥ 65 11 12 15 17 25
Race/ethnicity
American Indian/Alaska Native 4 4 4 4 4
Asianb 6 8 9 9 11
Black/African American 175 194 210 217 234
Hispanic/Latinoc 87 96 109 117 130
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 86 102 110 123 142
Multiracial 42 43 47 50 53
Exposure categoryd
Sexual contacte 291 334 367 390 437
Injection drug usef 6 8 9 10 10
Sexual contacte
and injection drug usef
65 63 65 66 65
Perinatalg 18 18 17 19 19
Otherh 20 24 31 35 43
Region of residencei
Northeast 77 80 89 94 101
Midwest 112 122 127 129 136
South 119 136 153 176 198
West 92 109 120 121 139
Subtotal 400 447 489 520 574
Additional gender identityj
Age at end of year 
13–14 0 0 0 0 0
15–19 3 5 6 4 4
20–24 26 30 39 36 49
25–29 46 47 46 53 65
30–34 34 41 58 69 73
35–39 34 38 41 38 39
40–44 21 20 18 24 33
45–49 27 26 26 32 33
50–54 17 18 21 19 22
55–59 16 17 18 14 16
60–64 9 10 8 14 14
≥ 65 6 8 11 12 13
Race/ethnicity
American Indian/Alaska Native 0 1 1 1 1
Asianb 2 5 5 6 6
Black/African American 102 109 118 128 141
Hispanic/Latinoc 63 67 76 81 97
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 45 49 58 64 79
Multiracial 27 29 34 35 37
Exposure categoryd
Sexual contacte 203 225 255 275 314
Injection drug usef 1 1 1 1 1
Sexual contacte
and injection drug usef
28 27 28 29 34
Perinatalg 3 3 3 3 3
Otherh 4 4 5 7 9
Region of residencei
Northeast 110 129 138 143 155
Midwest 37 40 52 59 67
South 72 72 79 81 90
West 20 19 23 32 49
Subtotal 239 260 292 315 361
Total 11,412 12,052 12,716 13,281 14,045

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
i Data are based on address of residence at the end of the specified year (i.e., most recent known address).
j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 18b. Transgender and additional gender identity persons aged ≥ 13 years living with diagnosed HIV infection, by year and selected characteristics, 2017–2021—United States and 6 dependent areas
2017 2018 2019 2020 (COVID-19 Pandemic) 2021
No. No. No. No. No.
Transgender womana
Age at end of year 
13–14 0 0 0 1 2
15–19 106 78 76 53 64
20–24 867 841 807 780 789
25–29 2,005 2,008 1,931 1,848 1,838
30–34 1,900 2,124 2,388 2,627 2,754
35–39 1,524 1,631 1,761 1,846 2,018
40–44 1,153 1,234 1,322 1,460 1,614
45–49 1,120 1,132 1,174 1,170 1,193
50–54 1,014 1,058 1,059 1,107 1,124
55–59 631 710 801 836 881
60–64 315 356 394 458 525
≥ 65 177 211 263 304 347
Race/ethnicity
American Indian/Alaska Native 44 51 55 59 64
Asianb 166 176 188 201 219
Black/African American 5,030 5,306 5,582 5,817 6,106
Hispanic/Latinoc 3,474 3,679 3,908 4,104 4,349
Native Hawaiian/other Pacific Islander 24 27 32 34 40
White 1,124 1,174 1,233 1,284 1,370
Multiracial 950 970 978 991 1,001
Exposure categoryd
Sexual contacte 8,954 9,498 10,062 10,567 11,185
Injection drug usef 22 26 27 27 30
Sexual contacte
and injection drug usef
1,654 1,670 1,688 1,676 1,684
Perinatalg 24 24 23 23 22
Otherh 158 165 176 197 228
Region of residencei
Northeast 2,786 2,928 3,039 3,126 3,256
Midwest 1,497 1,601 1,655 1,741 1,862
South 3,937 4,114 4,339 4,577 4,830
West 2,553 2,702 2,902 3,002 3,162
US dependent areas 39 38 41 44 39
Subtotal 10,812 11,383 11,976 12,490 13,149
Transgender mana
Age at end of year 
13–14 1 0 0 1 2
15–19 8 8 5 3 6
20–24 20 22 30 40 41
25–29 64 76 76 69 70
30–34 45 63 88 100 124
35–39 66 66 67 76 83
40–44 41 51 55 56 62
45–49 49 52 53 48 48
50–54 48 47 45 48 47
55–59 28 25 34 39 45
60–64 21 27 23 25 23
≥ 65 12 13 16 18 26
Race/ethnicity
American Indian/Alaska Native 4 4 4 4 4
Asianb 6 8 9 9 11
Black/African American 175 194 210 217 234
Hispanic/Latinoc 90 99 112 120 133
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 86 102 110 123 142
Multiracial 42 43 47 50 53
Exposure categoryd
Sexual contacte 292 335 368 391 438
Injection drug usef 6 8 9 10 10
Sexual contacte
and injection drug usef
66 64 66 67 66
Perinatalg 19 19 18 20 20
Otherh 20 24 31 35 43
Region of residencei
Northeast 77 80 89 94 101
Midwest 112 122 127 129 136
South 119 136 153 176 198
West 92 109 120 121 139
US dependent areas 3 3 3 3 3
Subtotal 403 450 492 523 577
Additional gender identityj
Age at end of year
13–14 0 0 0 0 0
15–19 3 5 6 4 4
20–24 26 30 39 36 49
25–29 46 47 46 53 65
30–34 34 42 58 69 73
35–39 34 38 41 38 39
40–44 21 20 18 24 33
45–49 27 26 26 32 33
50–54 17 18 21 19 22
55–59 16 17 18 14 16
60–64 9 10 8 14 14
≥ 65 6 8 11 12 13
Race/ethnicity
American Indian/Alaska Native 0 1 1 1 1
Asianb 2 5 5 6 6
Black/African American 102 109 118 128 141
Hispanic/Latinoc 63 68 76 81 97
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 45 49 58 64 79
Multiracial 27 29 34 35 37
Exposure categoryd
Sexual contacte 203 226 255 275 314
Injection drug usef 1 1 1 1 1
Sexual contacte
and injection drug usef
28 27 28 29 34
Perinatalg 3 3 3 3 3
Otherh 4 4 5 7 9
Region of residencei
Northeast 110 129 138 143 155
Midwest 37 40 52 59 67
South 72 72 79 81 90
West 20 19 23 32 49
US dependent areas 0 1 0 0 0
Subtotal 239 261 292 315 361
Total 11,454 12,094 12,760 13,328 14,087

Note. Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Risk factor data for transgender and additional gender identity persons aged ≥ 13 years are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
e For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
f Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
g Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
i Data are based on address of residence at the end of the specified year (i.e., most recent known address).
j Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 19a. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year, assigned sex at birth, and selected characteristics, year-end 2021—United States
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Sex at birth
Male 300 6.6 726 10.9 1,689 38.6 8,732 131.9 11,129 255.6 22,576 85.1
Female 299 6.9 630 9.9 644 15.4 1,842 29.0 2,065 49.2 5,480 21.6
Race/Ethnicity
American Indian/Alaska Native 1 1.3 3 2.7 16 22.5 42 38.5 46 64.3 108 24.8
Asianb 39 8.7 56 8.3 52 11.3 166 23.3 210 41.5 523 18.7
Black/African American 338 27.5 833 47.4 1,338 114.8 6,064 333.5 7,160 594.7 15,733 219.2
Hispanic/Latinoc 81 3.5 229 7.0 537 25.9 2,549 84.1 3,360 174.1 6,756 53.6
Native Hawaiian/Other Pacific Islander 0 0.0 3 11.4 5 29.4 14 54.8 13 75.7 35 33.7
White 88 2.0 148 2.2 269 6.0 1,307 19.1 1,811 39.8 3,623 13.5
Multiracial 52 13.7 84 16.4 116 37.6 431 98.1 590 217.7 1,273 66.6
Transmission Categoryd
Male sex at birthe
Male-to-male sexual contactf 5 248 1,290 7,698 9,848 19,089
Injection drug useg 0 2 5 71 126 204
Male-to-male sexual contactf
and injection drug useg
1 4 21 174 341 541
Heterosexual contacth 1 11 28 219 308 566
Perinatali 236 364 278 500 457 1,834
Otherj 57 97 67 72 50 343
Subtotal 300 6.6 726 10.9 1,689 38.6 8,732 131.9 11,129 255.6 22,576 85.1
Female sex at birthe
Injection drug useg 1 6 27 108 156 296
Heterosexual contacth 6 75 221 1,027 1,320 2,648
Perinatali 224 456 304 633 552 2,169
Otherj 69 93 92 74 38 366
Subtotal 299 6.9 630 9.9 644 15.4 1,842 29.0 2,065 49.2 5,480 21.6
Region of residencek
Northeast 94 6.7 242 11.5 345 23.1 1,557 71.1 1,980 141.1 4,218 49.2
Midwest 140 7.5 236 8.6 356 19.8 1,569 56.5 1,936 108.9 4,237 38.6
South 261 7.5 638 12.6 1,249 38.1 5,874 118.1 7,115 216.8 15,137 75.5
West 104 4.9 240 7.7 383 19.2 1,574 51.9 2,163 103.5 4,464 36.1
Totall 599 6.7 1,356 10.4 2,333 27.2 10,574 81.5 13,194 154.3 28,056 54.0

Note: Data for the year 2021 are preliminary and based on deaths reported to the Centers for Disease Control and Prevention as of December 2022. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

a Rates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b Includes Asian/Pacific Islander legacy cases (see Technical Notes).
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s assigned sex at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Data include transgender and additional gender identity persons.
f Includes individuals assigned male sex at birth, regardless of current gender identity, who have had sexual contact with other males, and individuals assigned male sex at birth who have had sexual contact with both males and females (i.e., bisexual contact).
g Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).
h Heterosexual contact with a person known to have, or with a risk factor for, HIV infection.
i Individuals were aged ≥ 13 years at time of diagnosis of HIV infection.
j Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
k Data are based on address of residence at the end of the specified year (i.e., most recent known address).
l Includes persons whose race/ethnicity is unknown.